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ABSTRACT 
Biopsies from 117 patients with proven cervical carcinoma were taken under anaesthesia 
immediately prior to radiotherapy. The Courtenay Mills soft agar clonogenic assay was 
used to determine the colony forming efficiency (CFE) of tumour cells from 
disaggregated tumours and the survival of these cells following radiation. Validation of 
the assay was carried out by demonstrating linearity of colony formation and production 
of radiation survival curves. The mean CFE was 0.18±0.49% (±lsd) with a range of 
0.003 - 4.28% (based on total viable nucleated cell counts) for 84 (72%) specimens. No 
significant association was demonstrated between in vitro growth and either clinical stage 
(r=0.02) or tumour differentiation (r=0.08). 
A wide range of values (0.13-0.97) for surviving fraction at 2Gy (SF2) was obtained 
with a mean value 0.44 (sd=0.19) for 77 tumours. There were statistically significant 
differences between the individual tumours (p=<. 001). Heterogeneity in intrinsic 
radiosensitivity was not demonstrated (p=0.3) when multiple biopsies were processed 
independently from 18 tumours. From analysis of variance of the SF2 results it appears 
that the surviving fraction below 0.4 and those above 0.7 which show significant 
differences in radiosensitivity between pairs of tumours (p=OO5). 
Differential cell counts were made on cytospin preparations of tumour cell suspensions. 
There was no correlation between either CFE or SF2 (r = -0.05, r=0.15, respectively) 
and the degree of lymphocyte (r = 0.12) or macrophage (r = 0.001) infiltration. 
Ki67 staining of 29 specimens gave a mean proportion of positively stained nuclei of 
20.5% (sd=23). The Ki67 index was not correlated with tumour stage (r=0.58), 
differentiation (r=0.02), CFE (r=0.04) or SF2 (r="0.07). 
Vascularity was assessed on paraffin sections of 87 tumours. The mean intercapillary 
distance (ICD) was 240µm (sd=37pm) and mean proportion of vessels was 2.68% 
(sd=1.64%). Clinical data from 35 patients with 2 year minimum follow-up revealed no 
significant difference between the mean ICD or mean proportion of vessels for the group 
of patients which had died or recurred and the group which remained disease free using 
t-tests (t=0.74, p=0.47, DF=32; t= 0.6, p=0.55, DF=29 respectively). 
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LIST OF ABBREVIATIONS 
APAAP - alkaline phosphatase - anti alkaline phosphatase 
CAM - cell adhesion matrix 
CFE - colony forming efficiency 
DAB - diaminobenzidine 
DMSO - dimethylsulphoxide 
FCS - foetal calf serum 
HPF - high power field 
HCTA - human tumour clonogenic assay 
ICD - intercapillary distance 
INT - iododinitrotetrazolium 
LI - labelling index 
MTT - 3-4,5 dimethyltriazol-2-yl) 25 diphenyl tetrazolium bromide 
PAP - peroxide alkaline phosphatase 
PBS - phosphate buffered saline 
PLDR - potentially lethal damage repair 
SF2 - surviving fraction at 2 Gy 
SLDR - sub lethal damage repair 
TAM - tumour associated macrophage 
TBS - tris buffered saline 
TIL - tumour infiltrating lymphocyte 
TLI - thymidine labelling index 
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1. 'INTRODUCTION 
1.1 CLINICAL BACKGROUND 
1.1.1 Incidence 
Survival rates of patients treated for invasive carcinoma of the cervix have shown little 
improvement over the last two decades. The overall 5 year survival is 54% and is 
dependent on initial tumour stage, ranging from 76% for stage I to 7% for stage IV 
(FIGO, 1988). In the UK, cervical carcinoma accounts for 3% of cancer deaths in 
women (2,170 deaths per annum, CRC Figs, 1989). Between 1950 and 1988 there has 
been considerable variation in the age specific mortality trends. There has been a 
decrease in mortality in women >45 years of age and an increase in younger women 
25-34 years, with the percentage of all deaths occurring in this group increasing from 2.5 
to 5.5% between 1971 and 1988 (CRC Figs, 1989). 
1.1.2 Prognostic Factors 
Within the group of patients who have stage I disease there is variation in the 5 year 
survival, depending on whether the pelvic lymph nodes are involved or not, with 5 year 
survival being 83% in the group with negative nodes and 54% with positive nodes 
(FIGO, 1988). At present, stage is the most important prognostic factor in`cervical 
carcinoma. Size of the primary tumour is important also, with local recurrence increased 
with bulky tumours (Jampolis et al, 1975; van Nagell, 1979; Perez et al, 1983), although 
the present staging system does not adequately take tumour volume into account (Hunter 
et al, 1986). The volume of disease has been shown to be predictive of nodal 
involvement as well as of outcome (Dembo et al, 1987). 
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Pelvic recurrence is significant in this disease and varies according to the stage of disease 
at presentation; 3-6% for stage I disease rising to 45% for stage III disease (Hunter et al, 
1986; Davidson et al, 1989). Approximately 35% of all patients with cervical cancer will 
have recurrent or persistent tumour and the cause of death in 60% of these patients is 
related to local failure, with 80% of these recurrences occurring within 2 years of 
treatment (Perez, 1988) and 94% within 3 years (Jampolis et al, 1975). Of these 
recurrences, 75% have been shown to be situated in the parametrium and 25% are central 
recurrences. The majority of patients with pelvic failure also have distant metastases 
(Perez, 1988). 
Tumour histology has been reported to be an important prognostic factor with some 
series demonstrating a less favourable outcome for adenocarcinoma of the cervix 
(Grundsell et al, 1979; Kapp et al, 1983; Milsom and Fribert, 1983), whilst others have 
shown no significant differences in outcome (Davidson et al, 1989; Grigsby et al, 1988). 
The histopathological grading of tumours gives useful prognostic information and in 
general histologically undifferentiated tumours have a poor prognosis. However, the 
morphological features of the cells do not identify all their biological properties (Tubiana, 
1987). Bloom (1965) and Kapp with his associates (1983) have indicated the importance 
and possible difficulties encountered in identifying histological grading of cervical 
carcinoma. The histological cell type, as classified by Wentz and Reagan (1959), has 
been shown to be important in prognosis (Ng and Atkin, 1973; Van Nagell et al. 1977; 
Randall et al, 1988), though tumour differentation was not shown to be important in 
some series (Gunderson et al. 1974; Goellner, 1976; Crissman et al, 1985; Benstead et 
al, 1986). Vascular/lymphatic permeation has also been shown to have a significant 
effect on outcome (Crissman et al, 1985; Perez, 1988). 
The prognostic importance of age has not been clearly defined (Dattoli et al. 1989). 
According to some investigators the prognosis is more favourable in younger patients 
(Russell et al, 1987; Meanwell et al, 1988) but has been shown to be an unfavourable 
factor in other series (Lybeert, 1987; Ashby et al, 1987; Elliot et al, 1989; Dattoli et al, 
1989). Of these factors, stage of disease, tumour volume and the presence of lymph 
node metastases are the most important factors which predict outcome. 
1.1.3 Prediction of Response 
Several predictors of tumour radiocurability are already used in clinical practice eg. 
tumour stage, size and histology, though these are non-specific and relatively imprecise 
(Brocket al, 1985; Peters et al, 1986). The aim of predictive assays in radiotherapy is to 
refine the discrimination of existing predictive factors. They can be classified as 1) direct 
or indirect measurement of tumour cell survival following irradiation and 2) measurement 
of cellular and extracellular parameters which may affect radiosensitivity (Peters et al. 
1986). There have been significant efforts recently to develop predictive assays based on 
tumour properties. A list'of potential predictive assays in clinical oncology is given 
below (reproduced in part from Mitchell, 1988). 
It is unlikely that a single assay will predict patient/treatment outcome alone but a 
combination of several may add to the value of existing prognostic indicators and enable 
the selection of patients at high risk of recurrence or who might benefit from treatment 
with another modality. 
1.2 INTRINSIC RADIO SENSITIVITY OF TUMOUR CELLS 
1.2.1 Surviving fraction at 2Gy 
"That certain tissues, particularly certain tumours, are sensitive, is the basic fact 
underlying all radiation therapeusis in tumours" (Paterson, 1933). Different tumour 
types were classified by Paterson (1933; 1936) into three groups according to their 
radioresponsiveness; radioresponsive (embryonic tumours, reticuloses), tumours of 
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intermediate radio responsiveness (squamous cell tumours and adenocarcinomas) and 
radioresistant (melanomas, soft tissue and bone sarcomas). The early work attempting to 
relate cellular radiosensitivity with treatment outcome of Glucksman (1941) involved 
histological examination of biopsies of carcinoma of the cervix before and after 
irradiation. Assessment of these was then used to try and predict local tumour control. 
Agreement between cytopathological prediction and clinical outcome was shown in 87% 
of 150 cases. This approach however had its difficulties with many of the 
post-irradiation biopsies being unsatisfactory (Dobbie et al, 1962). 
TABLE 1 (reproduced in part from Mitchell, 1988) 
POTENTIAL PREDICTIVE ASSAYS IN CLINICAL ONCOLOGY 
I. Direct effects of radiation on cells 
(a) tumour cell survival 
clonogenic assays 
(b) growth rate 
dye exclusion 
tritiated thymidine incorporation 
cell adhesive matrix 
MTT 
growth chamber 
(c) cellular damage 
DNA strand breaks 
micronuclei formation 
II. Parameters which may affect radiosensitivit 
i) tumour cell kinetics 
ii) DNA content/ploidy 
iii) tumour oxygenation 
p02 measurements 
iv) biochemical assays 
glutathione 
gene amplification 
membrane proteins 
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In the past it has been generally accepted that mammalian cells do not differ significantly 
in their inherent radiosensitivity. Lack of differences in the Do values of human tumour 
cell lines led to the conclusion that survival parameters obtained in vitro could not explain 
the differences in radiocurability between tumour classes (Weichselbaum, 1976; 1980). 
However, this is now known not to be the case. A report from the Gustave-Roussy 
Institute by Fertil and Malaise (1981), confirmed by the group from the Institute of 
Cancer Research (Deacon et al, 1984), showed that there is a correlation between the 
ability to control various classes of tumour and the clonogenic survival of cell lines 
(derived from these classes) following exposure to 2Gy. 
One hundred and one published cell survival curves for 92 human cell lines (including 64 
tumour lines) were analysed in terms of parameters used to characterise cell 
radiosensitivity (Fertil and Malaise, 1985). It was found that 1) the initial part of the 
survival curve is specific to the corresponding cell line, 2) this initial part of the curve is 
well described by the parameter and 3) human tumour cell line radiosensitivity in terms of 
the surviving fraction at 2 Gy (SF2) reflects the clinical radioresponsiveness of the 
tumours from which the cell lines are derived. These conclusions were made on the basis 
of published estimates of the Prescribed Tumour Lethal Dose for various tumour types 
(95% control dose for tumours of corresponding histology). The degree of the 
correlation raised the possibility that the initial slope of the survival curve may be a major 
determinant of the outcome of fractionated radiotherapy. The dose of 2Gy was chosen as 
this was a dose found by Fertil and Malaise (1981 and Malaise et al, 1989) to give good 
discrimination between the cell survival curves. It is also the dose per fraction commonly 
used in clinical radiotherapy. 
This work was further developed by Deacon et al who placed the tumour types into five 
categories of decreasing radiocurability with category A being radioresponsive and 
category E refractory (Table 2). 
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FIG. 1 The implications of the value of SF2 for 
response to a course of 30 fractions. The lower 
panel shows a plot of S= (SF2)30. Deacon et al, 1984. 
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TABLE 2 From Deacon et al (1984) 
Tumour types in decreasing order of controllability 
A. Neuroblastoma, lymphoma, myeloma 
B. Medulloblastoma, small-cell lung carcinoma 
C. Breast, bladder, cervix carcinoma 
Surviving fraction at 2Gy 
0.19 (0.08 - 0.37) 
0.22 (0.1-0.31) 
0.46 (0.3-0.58) 
D. Pancreas, colo-rectal, squamous lung carcinoma 0.43 (0.18 - 0.75) 
E. Melanoma, osteosarcoma, glioblastoma, renal carcinoma 0.52 (0.48 - 0.56) 
Experimental data from published survival curves were used to give further support for 
the importance of the clinical slope in a course of fractionated radiotherapy. Although the 
overall effect of fractionated radiotherapy will be modified by repair, reoxygenation and 
repopulation, the potential steep dependence of overall cell kill with the initial slope was 
indicated and differences in the SF2 values between category A and less sensitive groups 
were adequate to explain success or failure in achieving local tumour control (Fig. 1). 
1.2.2 Differential repair 
Large differences in repair capacity exist between cells. This has been demonstrated with 
studies looking at potentially lethal damage repair (PLDR or delayed plating repair) and 
split dose experiments to obtain a measure of sublethal damage repair (SLDR). PLDR 
has been found to vary among cell lines in vitro (Weichselbaum and Beckett, 1987) and 
repair capacity shown to vary amongst cell lines of the same histological cell type 
(Kelland and Steel, 1988). It has been suggested that differences in ability to repair 
damage may reflect differences in clinical radiocurability among corresponding tumours, 
with less responsive tumours exhibiting most PLDR (Weichselbaum and Beckett, 1987). 
More recent work has failed to find a correlation between the extent of PLDR and overall 
radio responsiveness of tumour type (Hall et al, 1988). 
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It has also been shown in recent work that radiosensitive cell lines may be efficient at 
repairing damage (Peacock et al. 1988). This has led to the suggestion that human cell 
lines may be "fully proficient in recovering from recoverable damage at doses below 
2Gy, and at dose rates below 2Gy/minute, they do so almost completely" and that SF2 
reflects the level of non-repairable radiation damage (Steel and Peacock, 1989). 
1.2.3 Primary Tumour Culture 
There are recognised limitations to studying the radiosensitivity of cell lines; - 
1) In general there is no information on the clinical radioresponsiveness of the original 
tumour from which each cell line is derived. 2) The morphological characteristics of the 
original tumour cells have generally changed (they are frequently less differentiated in 
culture than in patients). 3) Only a small fraction of the original tumour population may 
have given rise to an established cell line (Malaise et al, 1986). Correlations based on cell 
lines with values described by different laboratories where methodologies may vary are 
open to criticism regarding interpretation. It has been demonstrated that the choice of 
assay may influence radiation survival curve parameters (West and Sutherland, 1986). 
In vivo - in vitro comparisons in radiosensitivity have been made. Seven different cell 
lines were grown in vitro and as xenografts and SF2 was found to be considerably higher 
in vivo (Malaise et al, 1986). However, the contribution of one or more additional 
causes of radioresistance (eg. presence of hypoxic cells, proliferation of tumour cells 
during the course of treatment) does not weaken the correlation between the initial slope 
of the in vitro survival curve (inherent radiosensitivity) and the clinical 
radioresponsiveness. This was confirmed by the work of Rofstad et al (1987) on 
melanoma xenografts where the in vivo radioresponsiveness was positively correlated 
with the initial slope of the in vitro survival curve. 
Rofstad et al (1987) studied the radiation sensitivity of human tumour primary cultures 
17 
using the Courtenay-Mills soft agar assay. SF2 was measured for melanoma, ovarian, 
breast, bladder, seminoma and head and neck tumours. The survival at 2Gy differed 
considerably among tumours of the same histological type. The range of SF2 values for 
8 cervix tumours was 0.17 - 0.48 with a mean of 0.3. No significant difference was 
demonstrated between the mean SF2 values for the 7 tumour categories, but two thirds of 
the seminomas had a low SF2 value (< 2) and a third of the melanomas had a high SF2 
value. These data are consistent with the suggestion of Fertil and Malaise (1981;, 1985) 
and Deacon et al (1984) that the clinical radiocurability of tumours may be correlated to 
the cell surviving fraction at 2Gy. 
1.2.4 Rapid Assay of Radiosensitivity 
Recently Baker et al (1986; 1988) developed a human tumour primary culture technique 
which makes use of a cell adhesion matrix (CAM) for improving attachment of cells to 
culture plates and a highly enriched medium that support tumour cell growth. This 
technique measures growth of surviving cells rather than clonogenic survival. Briefly, 
the technique involves dissociation of a tumour biopsy into a single cell suspension. 
Twenty-four well plates, coated with CAM (a combination of fibronectin and 
fibrinopeptides), are inoculated with cells and incubated for 24 hours. Dead and 
non-adherent cells are removed and wells irradiated with graded doses of X-rays. The 
cultures are grown for 2 weeks, then stained with crystal violet and the total amount of 
stain uptake, expressed as optical density, measured by a video image analysis system. 
This measurement of staining density has been shown to be directly proportional to the 
total number of cells that have grown in each culture well and to be correlated with 
surviving fraction (Brock et al, 1985). With this method successful growth has been 
achieved in 80% of primary tumour specimens (Baker et al, 1986). One concern with 
this assay is the possible growth of normal cells that may be part of a tumour specimen 
(Mitchell, 1988). It has been reported that morphological, immunohistochemical and 
cytogenetic analyses of cultures grown from biopsies in this way, have shown that 
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normal cells were not present to a significant extent (Baker, 1986; 1988). However, an 
investigation, into the ability of CAM to support the growth of normal tissues, 
demonstrated a predominantly fibroblastic morphology (Head et at, 1989). Tumour 
cultures grown using this system by the same group found that lung and breast tumour 
cultures were highly contaminated with fibroblasts, although a greater degree of success 
was seen with ovarian tumours (89% of cultures had more than 50% epithelial cell 
morphology). 
Using this technique radiation sensitivity curves have been derived for a wide variety of 
tumour types including a series of head and neck tumours (Brock, 1985; 1989). These 
showed a wide range of SF2 values (0.10 - 0.91) with a mean of 0.33 (Brock, 1989). 
The radiosensitivity of tumour cells in primary culture was shown to vary from one 
tumour class to another in a way that is comparable to that observed for established cell 
lines (Malaise et al. 1989). Differences in SF2 for primary cultures and cell lines have 
been reported also (Malaise et al. 1987; Suit et al, 1989). Patient follow-up time is not 
yet long enough, though in time it will be possible to correlate these measurements of 
radiosensitivity with clinical outcome in the series of patients with head and neck tumours 
treated with surgery and radiotherapy (Peters et al, 1987). 
1.3 CLONOGENICITY 
The capability of a single cell to grow into a colony, which contains more than 50 cells, is 
a convenient proof that it has retained its reproductive integrity (Hall, 1978). The ability 
of single mammalian cells to proliferate into colonies was used by Puck and Marcus 
(1956) in a plating technique analogous to that used for the assay of bacterial cell 
viability. The loss of this ability as a function of radiation dose is described by the 
dose-survival curve. 
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Since its introduction in 1956, the tissue culture techniques for measuring 
colony-forming ability of mammalian cells have been used widely to define details of the 
shape and characteristics of cell survival curves, in the hope that this may provide insight 
to produce a better strategy for treating human tumours (Tepper, 1981). Tumours may 
contain proliferative cells which form a spectrum, from those with a limited number of 
potential divisions to those with the capacity to renew the entire cell population, including 
themselves (MacKillop, 1983; Selby, 1983). These self-renewing and 
population-renewing cells, which may constitute only a small proportion of the total 
population, are known as stem cells (Tepper, 1981). It may be that it is these stem cells 
which are responsible both for tumour repopulation after treatment and also for metastatic 
growth, and are therefore the primary target for any cytotoxic therapy of cancer (Selby et 
al, 1983). 
Although it has been postulated that clonogenic assays can be used for the study of stem 
cells (Bruce et al, 1969), studies have shown that relatively few clonogenic cells have 
renewal capacity in culture (Buick and MacKillop, 1981). It may be that within the cell 
hierarchy there exists cells with high proliferative potential but that have no (or limited) 
self-renewal capacity. Therefore it is not yet known whether clonogenic assays can 
quantify tumour stem cells (MacKillop et al, 1983). 
1.3.1 Choice of Assay 
Different 'culture techniques are available for growing colonies directly from a variety of 
human tumour specimens (Hamburger and Salmon, 1977; Courtenay and Mills, 1978). 
A semi-solid medium suppresses the growth of most normal cells, though benign 
epithelial or stromal cells (Pavelic, 1980) and haemopoietic cells may occasionally 
proliferate (Hamburger et al, 1978), and allows the growth of cells capable of anchorage 
independent growth. 
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There is plenty of evidence of the malignant nature of the colonies from cytology (Salmon 
and Buick, 1979), cytogenetic studies (Trent, 1980), studies on secondary plating 
efficiency (Singletary, 1985) and the ability of these colony cells to produce tumours in 
nude mice (Pavelic, 1980). 
A number of tumour classes have been studied with regard to clonogenicity; notably 
breast carcinoma, malignant melanoma and ovarian carcinoma (Hamburger, 1978; Tveit, 
1981; Bertoncello, 1982; Ottestad, 1989). Relatively few studies have concentrated on 
cervical carcinomas and widely different success rates in growing colonies have been 
reported. Eighty eight per cent of 76 specimens grew in a study by Parker et al (1984) 
and only 1% (1/29) in a study by Williams et al (1983). The Hamburger-Salmon assay 
has been widely used since 1978 and a number of clinical trials have been carried out 
using this method in order to test for the validity of using clonogenic assays to predict 
clinical response to chemotherapy (Bertelson et al, 1984; Von Hoff, 1988; 1990; 
Salmon, 1990). However, it has been shown that the Courtenay-Mills assay yields 
higher colony-forming efficiencies than both the Hamburger-Salmon (Tveit et al, 1981; 
Endresen et al, 1985; Ottestad, 1988) and the Carney method, which utilised agarose 
instead of agar (Walls and Twentyman, -1985). 
The improved clonogenicity in the Courtenay method is due primarily to the presence of 
rat red blood cells and low oxygen tension although the replenishable nature of the assay 
allows for long incubation periods often necessary for specimens cloned directly from the 
patient (Walls and Twentyman, 1985). Low oxygen tension of 5% produces a higher 
CFE than 20% oxygen shown by Tveit et al (1981), Courtenay and Mills (1978; 1984) 
and Gupta and Eberle (1984) showed that although there was great variation between the 
CFE of cells from various human xenograft lines tested, the optimal concentration could 
be as low as 0.1 %. Bradley et al (1971) first demonstrated that washed rat and murine 
red blood cells improved the clonogenicity of murine marrow cells in agar and produced 
larger colonies. Using human tumour xenografts, Courtenay and Mills (1978) found that 
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red blood cells lysed before use were less effective than whole cells and that the time of 
lysis of the red blood cells in culture is important. This is in contrast to the findings of 
Besch et al (1986) who found that intact or lysed red blood cells improved the colony 
forming ability of breast tumour cultures. Pavelic et al (1980) did not demonstrate any 
increase in CFE using murine or rat red blood cells. The same report found no difference 
in the species of rat used to provide the red blood cells, though August rat red blood cells 
were found to consistently enhance colony growth of human and animal tumour cells in 
primary culture by Courtenay et al (1978) and Tveit et al (1981). Culture conditions can 
be improved and clonogenicity increased by supplementing the culture medium with 
growth factors and hormones. Studies involving primary human breast carcinoma cells 
have shown that improvements in CFE of 5 and 35 fold are possible (Hug et al, 1984; 
Besch et al. 1986; Ottestad et at, 1988). Epidermal growth factor (Hamburger et at. 
1981; Pathak et al, 1982), irradiated lymphoblast feeder layers (Hamburger, 1983), a 
combination of cell line-conditioned medium and growth factors (Hug, 1984), 
conditioned medium from murine splenic cells (Hamburger and Salmon, 1977) and 
boiled rather than autoclaved agar (Thomson et al, 1983), have all been reported as 
promoting the growth of human tumour cells in semi-solid medium. The addition of 
hydrocortisone and insulin have been shown to improve colony growth by several 
groups (Hug et al, 1984; Kern et al. 1984; Hamburger, 1987) as has the addition of 
transferrin (Calvo et al, 1983). 
1.3.2 Validity and Limitation of Clonogenic Assays 
Primary human tumour clonogenic assays have been criticised because of. 1) the low 
proportion of tumours suitable for testing, 2) difficulties in preparing single tumour cell 
suspensions, 3) low CFEs and 4) the scoring of small colonies. The proportion of 
human tumours which grow with a sufficient colony forming efficiency for assessment 
of radiosensitivity or chemosensitivity is often less than 50% (Bertoncello et al, 1982; 
Selby et al, 1983) and may range from 35 - 81 % depending on the research group, the 
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tumour type and definition of colony size (Singletary et al, 1985). In a large series of 
1,014 human solid tumours (Kern et al. 1982), 690 (68%) of these tumours of various 
histologies showed evidence of colony formation within 2-4 weeks. The cloning 
efficiency of fresh human tumour samples is low compared to that of established cell 
lines with values, in general, ranging from 0.001 to 0.1%. 
The presence of clumps and clusters in tumour cell suspensions has been observed by 
Agrez et al (1982) who used a human tumour clonogenic assay for 455 tumours and were 
not able to obtain preparations with exclusively single cells. Similar problems were 
recorded by Singletary et al (1985). In another series reported by Bertoncello et al (1982) 
difficulties in preparing single cell suspensions were found in 12% of ovarian tumour 
specimens, with only 36% of these tumours being adequate to culture. Alley and Lieber 
(1984) reported the presence of clumps and clusters in cell suspensions derived from 
human solid tumours and suggested filtration of cell suspensions, counts at Day 1, vital 
staining with a tetrazolium dye to facilitate colony counting and the use of 20Gy irradiated 
samples as negative controls to check for the presence of cells clumps in order to 
minimise errors. 
The lack of a true radiation survival curve generated in early reports of soft agar 
clonogenic assays have been cited as a major criticism of their validity (Selby et al, 
1983). A plateau in radiation survival curves would indicate the presence of clumps and 
clusters in the tumour cell suspensions' (Rockwell, 1985). Meyskens et al (1983) 
suggested that initial survival curves obtained with the Human tumour clonogenic assay 
(HTCA) indicating radioresistance may have been artefactual due to the presence of 
clumps plated initially. It was suggested that these difficulties could be circumvented by 
counting "colonies" immediately after plating and subtracting the initial number of clumps 
from the final colony counts (Alley and Lieber, 1984; Hamburger, 1987). However, this 
practice is frought with theoretical and practical difficulties demonstrated by Rockwell 
(1985). 
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Technical artefacts can lead to a lack of linearity between cells plated and colonies formed 
(Eliason, 1985). The relationship between colony numbers and concentration of cells 
plated is a important parameter of clonogenic assay systems. The cloning efficiency for 
an ideal sample should be independent of cell concentration, thus giving a straight line 
through the origin when colony numbers are plotted against cell concentration. Linear 
relationships have been demonstrated between the numbers of colonies formed and the 
numbers of cells plated (Hamburger, 1978; Pavelic, 1980). Tumour samples have been 
reported to show increasing cloning efficiences with increasing cell concentration and 
also decreasing cloning efficiencies at high cell concentrations (Eliason, 1985; Page, 
1988; Meyskens, 1983). 
It has been shown that lethally irradiated tumour cells are capable of completing up to six 
divisions before dying thus producing abortive colonies (Nias, 1965). The 50 cell 
colony is therefore a minimum size for accurate assessment of cell survival in radiation 
studies. It is uncertain how often abortive colonies form after drug therapy (Courtenay, 
1984). Counting colonies larger than 50 cells helps to minimise errors from cell clusters 
introduced into the cell suspension. Besch et al (1986), using an agar method, found 
identification of proper colony size to be a major obstacle in quantitating cell survival after 
radiation. Apparent radiosensitivity of tumour suspensions varied directly with the size 
used to define a colony. ý The use of stringent criteria for colony size resulted in 
conventional survival curves (Hamburger, 1987). A, colony may be defined as one with 
a minimum horizontal diameter of 60 to 100 microns for the cell cluster. The number of 
cells in a three dimensional system is difficult to quantify and therefore not as precise a 
criterion as diameter (Singletary et al, 1985). The number of cells in a tumour colony has 
been demonstrated to depend on the size of the individual cells and an empirically derived 
formula has been used to quantitate the number of cells within a tumour colony 
(Meyskens, 1984). 
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Setting the colony size at a higher number of cell divisions reduces the overall cloning 
efficiency but yields more accurate assessment of true sensitivity (Nias and Fox, 1968). 
1.3.3 Clonogenicity and Tumour Differentiation 
The relationship between the colony forming ability of tumour cells in soft agar and the 
prognosis of the patient has been studied by various groups and is of considerable 
interest. Results from these studies (Table 3) have been inconsistent and often small 
numbers have been evaluated. Thus no clear conclusions can be drawn (Ottestad, 1989). 
It has been reported that cancer cell clones that grow in semi-solid medium may represent 
the most malignant and rapidly growing fractions of the heterogeneous population of 
primary tumours (Hug et al, 1985; Moezzi et al, 1986; Flentje et al, 1987). CFE has 
been shown to be both correlated (Moezzi et al, 1986; Gioanni et al, 1988) and not 
correlated (Smallwood et al, 1984; Dittrich et al, 1985; Trotter et al, 1985; Aapro, 1987; 
Cobleigh et al, 1987) with tumour grade. Similarly correlation (Mattox et at, 1980; Von 
Hoffet al, 1980; Bertoncello et al, 1982; Miller et al, 1983; Sutherland et al, 1983; Johns 
and Mills, 1983; Hug et al, 1985; Aapro, 1985; Nomura et al, 1989) and lack of 
correlation (Mattox, 1984; Dittrich et al, 1985; Stevenson' et al, 1989; Ottestad et al, 
1989) with prognosis have been reported. Out of nine breast cancer studies, two have 
shown a correlation, whilst three showed no correlation with patient prognosis. 
Tumour growth in the clonogenic assays reflects a biologically important potential, 
related in at least some tumours to an abnormal DNA stemline (Verheuen et al. 1985). 
Smallwood et al (1984) demonstrated that the oestrogen receptor negative breast tumours 
had a higher Labelling Index (LI), but were not different from tumours which grew in the 
clonogenic assay and no correlation was demonstrated between CFE and tumour grade. 
Trotter et al (1985) also failed to demonstrate any relationship between thymidine 
labelling index and CFE in a series of twenty-eight colorectal tumours, whereas Gioanni 
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TABLE 3I 
STUDIES INVESTIGATING CLONOGENECITY 
AND CLINICAL OUTCOME 
Tumour type No. patients Conclusion Reference 
Head and neck 33 Mortality increased Mattox, 1980 
when CFE >0.02% 
Neuroblastoma 18 Survival -4 weeks if Von Hoff, 1980 
CFE >0.1% 
Ovary 29 Survival inversely Bertoncello, 
related to CFE 1982 
Lung 33 CFE >0.007% - 14 mth Miller, 1983 Survival <0.007% - 27 mth 
Breast 66 Mortality greater with 
hi h C 
Sutherland, 
983 g er FE 1 
Head and neck 29 Mortality greater with hi h C 
Johns, 1983 
g er FE 
Breast 54 CFE correlates with Smallwood, 
receptors not grade 1984 
Head and neck 157 CFE not related to Mattox, 1984 
survival 
Breast 31 Survival inversely Hug, 1985 
related to CFE 
Breast 87 No correlation with Dittrich, 1985 
grade or survival 
Colorectal 28 No correlation with grade Trotter, 1985 
Mixed 44 High CFE associated with Aapro, 1985 
poor prognosis 
Breast 268 CFE correlated with grade Moezzi, 1986 
Breast 61 CFE not correlated with Aapro, 1987 
tumour grade 
Head and neck 21 CFE not correlated with Cobleigh, 1987 
tumour grade 
Breast 59 CFE correlated with grade Gioanni, 1988 
Lung 68 CFE not related to prognosis Stevenson, 
1989 
Breast 138 CFE not related to prognosis Ottestad, 1989 
Breast 254 CFE related to metastatic Nomura, 1989 
potential of breast carcinoma 
Ovary * 121 CFE not correlated with Tveit, 1989 
grade: high CFE associated 
with poor prognosis 
* Courtenay-Mills assay used 
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et al (1988) showed that the tumours which grew in vitro had a higher LI than those 
which failed to grow. 
1.4 INFLAMMATORY CELL INFILTRATES 
1.4.1 Macrophages 
Cell suspensions prepared from tumours may contain a large number of inflammatory 
cells with reported values for the proportion of macrophages ranging from 0-67% (Gauci 
and Alexander, 1975; Steele et al, 1984; Kelly, 1988). Host cell infiltrates have been 
reported to be unevenly distributed throughout a tumour being concentrated at the tumour 
periphery (Normann, 1985). As most studies which have quantified the numbers of 
macrophages in tumours have relied on methods involving tumour disaggregation, 
samples for disaggregation taken at the centre of a tumour may have higher 
tumour/macrophage ratios than samples along the invading margin of the tumour. Using 
these methods, different tumour-host cell ratios may be obtained when compared with 
earlier studies using conventional tissue sections. Early studies also experienced 
problems in the identification of macrophage cells as it is difficult to identify these cells 
with accuracy by light microscopy of conventionally stained tissue sections (Underwood, 
1974). The 'tumour associated macrophages (TAM) recovered may be a selected 
population with losses occurring with disaggregation of the tumour (Takeo et al, 1986). 
The work of Eccles and Alexander (1974) on experimental murine tumours demonstrated 
that tumours containing high numbers of macrophages showed less tendency to 
metastasize than those with lower numbers. A number of susbsequent studies showed 
that tumour associated macrophages react with tumour cells and can stimulate tumour 
growth in some experimental tumours (Mantovani, 1979; Evans, 1977). However, more 
recent studies (Talmage, 1981) on the role of TAM showed no correlation between the 
macrophage content and the metastatic propensity of several murine and rat tumours, 
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including tumour variants obtained from metastases of these tumours. The role of TAM 
in 77 patients with lung cancer was examined by Takeo et al (1986) and no correlation 
was found between the numbers of TAM recovered and the recurrence rate. This was 
also found to be the case when TAM density and prognosis was studied in 
nasopharyngeal cancer (Nomori, 1984). However, Steele et al (1984) examined the 
macrophage content of forty breast tumours and found that increased numbers of TAMs 
were in fact associated with factors that indicate a poor prognosis. As many factors 
influence the metastatic behaviour of tumours perhaps it is unreasonable to expect that 
macrophage content alone would show a good correlation with metastatic spread. The 
anti-tumour activity of TAM, not just the proportion of TAM recovered, may be of use in 
predicting patient outcome (Takeo, 1986). 
Macrophages have been shown to promote tumour cell growth in vitro (Buick et al, 1980; 
Mantovani et al, 1979; Gabizon et al, 1980; Hamburger et al, 1983) and in vivo (Evans, 
1977). There is evidence that this growth promotion is mediated by soluble factors 
(Gabizon, 1980). These factors may be the same or similar to those released by 
peripheral blood monocytes which enhance the growth of human tumours in soft agar 
and appear to be heat stable, non-dialyzable, acid labile proteins of 10,000 - 30,000 
daltons (Hamburger, 1986; 1987). 
The relationship between the degree of host cell infiltration of a tumour and its response 
to therapy has been less well studied. An investigation using murine tumours 
demonstrated that the TAM content was related to the radioresponsiveness of these 
tumours, with higher macrophage content conferring radioresistance (Milas et al, 1987). 
No correlation between TAM content and the growth rate of established tumours or 
metastatic spread was seen. The suggestion from this work was that the tumour 
macrophages may promote the survival of the tumour cells not killed by radiation. 
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Despite extensive investigation, the role of macrophage infiltration in the metastatic 
behaviour of malignant tumours remains uncertain. Little information is available on the 
association between the extent of macrophage infiltration and tumour progression 
parameters other then metastatic spread and also little on the association between TAM 
content and tumour response to therapy (Milas, 1987). It is clear that this role is not a 
simple one and that TAM are functionally heterogeneous (McBride, 1986). 
1.4.2 Lymphocytes 
The role of tumour infiltrating lymphocytes (TILS) has also been the subject of much 
investigation. The degree of infiltration has been associated with prognosis, with higher 
numbers of TILS being associated with longer survival (Underwood, 1974; Black et al, 
1971; Hiratsuka, 1984; Svennevig, 1985; Yasumoto, 1988). This observation is often 
cited as evidence for an immunological response to tumours, although this is not 
universally accepted (Krieder, 1984). The true position may also be obscured by a 
publication bias for papers demonstrating a positive association with prognosis and a 
reluctance to publish negative or inconclusive results (Underwood, 1974). Another 
important factor is the absence of quantitative, morphometric measurements and of 
reliable sampling methods, applied to either conventional tissue sections, or to living cell 
suspensions obtained from dissociated tumours (Kreider, 1984). 
More recent studies have looked at types of TILS inhuman solid tumours using 
monoclonal antibodies and have shown the vast majority tobe T-lymphocytes 
(Whiteside, 1986; Miescher, 1988). Studies to examine their function have been made. 
Some studies have shown that freshly isolated populations of TILS from different solid 
tumours had depressed natural killer cell activity (Eremin, 1981; Moy, 1985), although 
this is not true in all cases (Meischer, 1987).. It has been suggested that the poor 
cytotoxic actions of TIL populations may be related to cell numbers inadequate for 
analysis, low proportions of effector cells among TILS, possible inhibitory influences of 
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tumour environment (Meischer, 1986) or possible suppressive factors produced by cells 
in TIL populations (Vose and Moore, 1979). Lymphocyte-derived soluble mediators 
may play an important role in regulating the anti-tumour activity of TAMs in lung cancer 
because of the co-existence of a large number of lymphocytes in lung cancer tissues 
(Yasumoto et al, 1988). Cytolytic T lymphocyte precursors are present in human solid 
tumours but vary considerably amongst individual tumours (Meischer, 1987). A study 
on 100 patients with colorectal tumours supported the view that human tumours attract 
mononuclear cells and that this local reaction may influence prognosis, but the value of 
this parameter may be limited because of the great variance in the inflammatory reaction 
within the same group of survivors (Svennevig, 1984). No firm conclusions regarding a 
causal relationship between host cell infiltration in human tumours and prognosis can be 
made. 
1.4.3 Eosinophils 
The association of a malignant tumour with eosinophilia and tumour eosinophilic 
infiltrates has been long recognised (Pretlow, 1983). Cervical carcinoma is usually 
associated with a mixed chronic inflammatory infiltrate in the surrounding stroma (around 
the tumour cells), but in a small number of cases there is massive stromal infiltration by 
eosinophils (Lowe, 1988). A retrospective series of 1027 cases of cervical carcinoma 
revealed massive eosinophilia (>100 eosinophils per high power field) in 3% of cases 
(Lowe, 1988). From this study it was found that patients with massive eosinophila, who 
had no circulating eosinophilia, had a better prognosis than tumours without. Five 
patients who had a circulating eosinophilia, as well as eosinophilia within the tumour, 
had extensive disease and short survival. Other workers have also found tumour 
eosinophilia in cervical carcinoma to be associated with a favourable prognosis (Pastrnak, 
1984). Marked eosinophilia was found to occur within 4% of these tumours which is 
similar to the incidence reported by Lowe (1988). Ina smaller series tumour eosinophilia 
was reported not to be associated with prognosis, whle eosinophilia of the peripheral 
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blood was reported to be an adverse prognostic sign (Bostrom, 1981). There are two 
possible explanations for tumour eosinophilia: - 1) the tumour cells may directly 
manufacture eosinophil chemotactic factors and 2) the presence of eosinophilia might be 
part of a specific reaction of the host against the tumour (Bostrom, 1981; Pastrnak, 
1984). 
1.5 VASCULARITY 
In view of the radiobiological effect of oxygen, knowledge of the extent to which 
tumours are oxygenated may be important in predicting local tumour control by 
radiotherapy (Peters et al, 1986). Information on the vascular supply of tumours can be 
of great value in reflecting the degree of oxygenation of the tissue but relatively little 
attention has been paid to it on routine histo-pathological classification of human tumours 
(Siracka, 1988). This is possibly due to the lack of methods useful in clinical practice for 
reliable quantitation of vascularity in biopsies. 
1.5.1 Intercapillarydistance 
Vascularisation in carcinoma of the cervix has been studied by Kolstad (1968) using 
colpophotography. Assessment of the oxygenation of the tumour surface was made, 
using intercapillary distance as a parameter, and revealed a decrease in oxygenation with 
advancing stage of disease. This observation was confirmed by direct measurement of 
the tissue oxygen tension. The critical intercapillary distance was found to be 
approximately 350µm, since above this distance the incidence of necrosis rose rapidly. 
Kolstad (1968) was able to demonstrate a 51% local recurrence rate among 51 patients 
whose tumours had largest intercapillary distances greater than 400µm, compared to a 
17% recurrence rate in 54 cases with greatest intercapillary distances less than 400pm. 
There also appeared to be different vascularisation patterns for adenocarcinomas and 
squamous cell tumours and the suggestion was made that these should be considered 
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separately when assessing the vasculature. These significant findings were confirmed by 
Awwad et al (1986) who measured intercapillary distance by a more precise though 
laborious method of analysing histological samples from 44 patients with Stages IIB and 
III disease of the cervix. This method involved a histochemical procedure to stain 
capillary endothelial cells and a projection/tracing technique was used to make the 
measurements. The mean intercapillary distance (304±30µm) was shown to be greater 
(322µm) in those patients who developed local recurrence within two years than in those 
whose tumours were controlled - 291µm (Awaad, 1986). This finding was shown to be 
independent of tumour stage and grade. However, in a series of 26 oral squamous cell 
carcinomas reported by Lauk and associates in 1989, the group of patients which had 
local control had an average median distance betwen tumour cells and blood vessels of 
105pm, compared with a median distance of 76µm in the group of patients which failed 
treatment. The finding of a higher local control rate in oral squamous cell tumours which 
were less well vascularised is contradictory to the studies on cervical carcinoma. This 
may be because of biological differences between oral tumours and cervical carcinoma 
and/or incomparable treatment schedules (Lauk et al, 1989). 
1.5.2 Morphometric analysis 
Another method of analysing the vasculature of cervical carcinoma has been employed by 
Siracka and colleagues (1982; 1984) who made morphometric measurements of relative 
volumes of stroma, parenchyma and blood vessels. The tumours of 23 patients' 
surviving more than 5 years following radiotherapy were found to have a stroma that was 
rich in blood vessels, compared to those of 22 patients who died within 5 years. The 
results of this retrospective study confirm Kolstad's observations that vascular density in 
cervix cancers is related to the radiocurability of the disease. A further retrospective 
study of the capillary density in nasopharyngeal tumours showed a statistically significant 
correlation between capillary density and survival time of patients treated with 
radiotherapy (Delides eta], 1988). 
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Intra-tumour variation of vascularity was investigated in addition to the variation between 
tumours (Siracka et al, 1988). It was found that there was a more or less individual 
pattern of vascularisation of the tumours despite a considerable intra-tumour variation of 
the vasculature. In the case of stage IB cervical cancers, the variation of vascular density 
between tumours was greater than that within them' (Siracka et al, 1988). This finding 
was confirmed for more advanced tumours (IIA and III included) when surgically 
removed carcinomas were studied by taking biopsies from different sites (Revesz et al, 
1989). In a further study of vascularity in cervical carcinoma, vascular density was 
shown to be superior to tumour grading with respect to prognostic values (Siracky et al, 
1988). 
For experimental squamous cell carcinomas, it has been shown that quantitative 
measurements of vascular sections may be of prognostic significance in that there was a 
positive association between relative vascular volume and radiation response in situ 
(Moore et al, 1985). 
1.6 TUMOUR CELL PROLIFERATION 
In previous decades considerable interest was given to the influence of tumour growth 
rate on the course of the disease. The incidence of mitotic figures in human tumours is 
the most direct indicator of cell production and has long been used by pathologists as a 
guide to proliferative activity. The discovery of the cell cycle by Howard and Pelc and 
the description by Taylor and colleagues of the thymidine labelling index (TLI) in the 
1950's provided a new approach to tumour growth kinetics (Tubiana and Courdi, 1989). 
In each histological group of human tumours the individual values of the TLI vary widely 
although there are significant differences between means of each group. The highest 
mean TLIs were found in lymphomas and * embryonal tumours and lowest in 
adenocarcinomas (Steel, 1977). The mean TLI was highest in the groups of tumours 
which respond to radiotherapy and chemotherapy (Tubiana and Courdi, 1989). There is 
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a corrrelation between the mean doubling time and TLIs within each histological group 
and the highest TLIs were seen in undifferentiated tumours compared to differentiated 
tumours of the same type (Tubiana and Courdi, 1989). 
The proliferative activity of tumour cells measured by TLI has been reported to have 
prognostic value in breast carcinomas (Meyer et al, 1983; Tubiana et al, 1984; Silvestrini 
et al, 1985; 1989). TLI has also been shown to be of prognostic value in head and neck 
tumours with survival being lower in those patients with a high TLI (Chauvel, 1989). In 
a small series by Dixon and associates (1977) they were unable to demonstrate significant 
differences in TLI in those patients who relapsed compared to those who were cured. 
The measurement of TLI however is labour intensive and requires at least 10 days for 
processing and has never been used routinely (Tubiana and Courdi, 1989). 
Flow cytometry has been used more widely to estimate the proportion of proliferating 
cells. The measurement of DNA content distribution provides evidence of ploidy 
abnormalities and approximately the proportions of cells in various phases of the cell 
cycle. The proportion of cells in S phase can be determined and has been shown to 
correlated with TLI (Tubiana and Courdi, 1989). The DNA content and S phase fraction 
have been found to be predictive of relapse-free and overall survival in breast cancer 
(Dressler et al, 1987; Kallioniemi et al, 1988), in carcinoma of the rectum (Streffer et al, 
1986), ovarian tumours (Kallioniemi et al, 1988) and as a predictor of early recurrence in 
cervical carcinoma (Strang et al, 1987). 
1.6.1 Ki67 staining 
The Kiel group (Gerdes et al, 1983; 1986) has reported that a monoclonal antibody Ki67 
specifically stains cycling cells. The antibody has been developed which identifies a 
nuclear antigen in human cells at all stages of the cell cycle except resting cells in Go 
(Gerdes et al, 1984). The exact nature of the antigen recognised by Ki67 has not yet 
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been determined and its functional role is unclear. It has been used to measure the 
tumour growth fraction. The growth fraction a LI/(LI)p where LI is the labelling index 
of the whole population and (LI)p is the labelling index of proliferating cells. A 
correlation has been demonstrated between the immunohistochemical labelling of cell 
nuclei with Ki67 and other methods of assessing cell proliferation - namely mitotic index 
in breast cancers (Barnard et al, 1987) and soft tissue sarcomas (Ueda et äl, 1989) and in 
cell lines with tritiated thymidine uptake (Gerdes, 1984) and uptake of 
bromo-deoxyuridine in Non Hodgkin's lymphoma (Schrape et al, '1987) and S-phase 
fraction in breast cancers (Walker and Camplejohn, 1988). 
Ki67 index was shown to be closely correlated with tumour grade in Non Hodgkin's 
lymphoma and breast carcinomas with the less differentiated tumours containing a higher 
proportion of Ki67 positive cells (Schrape et al. 1987; Barnard et al, 1987; Lelle et al, 
1987; Bouzubar et al, 1989). The extent of nuclear staining did not correlate with the 
degree of differentiation in Walker and Camplejohn's breast study (1988) in contrast to 
the findings reported by Gerdes et al (1986) on breast tumours where the extent of 
nuclear staining was correlated to the tumour grade. However, no significant relationship 
between the percentage of cells labelled with Ki67 and tumour grade, cell type or mitotic 
index was demonstrated in a study on cervical carcinoma (Brown et al, 1988). 
There was a wide range of cells that were labelled by Ki67 in the study on cervical 
tumours (10-50%), although a smaller variation of 10% amongst different areas of the 
same tumour biopsy was demonstrated (Brown et al, , 1988). A similar range of labelled 
nuclei was seen (5-60%) in breast tumours but in 26% of tumours cytoplasmic staining 
was the only staining seen and 18% of specimens exhibited no staining (Walker and 
Camplejohn, 1988). The significance of this cytoplasmic staining is not known but it has 
been shown to be unrelated to proliferative activity (Gerdes et al, 1983). Aneuploid 
tumours have been shown to have a higher frequency of nuclear staining than diploid 
tumours. 
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Heterogeneity of Ki67 staining was marked in many carcinomas so greater numbers of 
cells were counted in the study of Walker and Camplejohn (1988) compared to the 
studies of Gerdes et al (1986) and Le11e et al (1987) and this may account for the lower 
percentage of nuclear staining seen in this study. The distribution of labelled nuclei 
varied within the individual tumours with areas of cell maturation and keratinisation 
showing little or no staining compared to peripheral portions which are more actively 
proliferating (Brown, 1988). The staining of nuclei with Ki67 was demonstrated to be 
confined to epithelial cells only, using a double staining procedure on fine needle 
aspirates of breast carcinomas (Charpin, 1989). This contrasts with the findings of 
Bouzubar et al (1989) who demonstrated antibody binding in the nuclei of benign 
components, but this was not found to be above 5%. In the study on Ki67 staining in 
breast carcinomas of Lelle et al (1987) the average numbers of Ki67 - positive cells was 
15% (range 1-48%) for breast tumours and 4% (range 1-10%) for benign breast lesions. 
The most important issue raised with the studies on Ki67 antibody staining is whether or 
not the variation in nuclear labelling with Ki67 (an objective measurement of cell 
proliferation) correlates with clinical behaviour. Retrospective studies are not possible 
with Ki67 because fresh (or frozen) tumour material is required as the epitope recognised 
by the antibody does not survive conventional fixation and processing (Hall et al, 1988). 
A high level of Ki67 staining was shown to be associated with early recurrence of breast 
carcinoma after mastectomy (Bouzabar, 1989). In a smaller series of patients with soft 
tissue sarcomas, the Ki67 index (number of positive tumour cells/10 High power fields) 
was shown to be correlated with patient outcome and was correlated with other 
prognostic factors (Ueda et al, 1989).. The Ki67 score (positive cells/total tumour cells) 
was shown to be independent of lymph node status which is an important prognostic 
factor in breast carcinoma (Barnard et al. 1987; Bouzubar et al, 1989), though this was 
not supported by Lelle's data which suggested that the average number of Ki67 positive 
cells was slightly higher in node positive patients. 
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1.7 AIMS 
The aims of this study were to evaluate potential prognostic factors for individuals with 
cervical carcinoma being treated with radiotherapy. 
1. Radiosensitivity. Surviving fraction at 2Gy will be determined for primary 
cultures of tumour biopsy specimens cultured using the Courtenay-Mills soft 
agar clonogenic assay. The adequacy of the assay will be established and 
sampling errors, resolution, reproducibility, intra-tumour heterogeneity and 
inter-patient variation will be investigated. 
2. Clonogenicity. The relationship between clongenic ability and both established 
clinical prognostic indicators and other potential prognostic factors will be 
studied. 
3. Vascularity. A prospective analysis of histological specimens taken from 
patients whose tumours were assayed for radiosensitivity is to be carried out. 
Intercapillary distance will be measured for each tumour along with 
morphometric analyses of stroma, parenchyma, necrosis and vascular 
components. A comparison of the two methods will be made. 
4. Inflammatory infiltrates. The proportions of normal host cell infiltrates in 
tumour cell suspensions will be examined. The relationships between these and 
other parameters studied are to be investigated. 
5. Ki67. The Ki67 index of the specimens will be determined and correlated with 
the other parameters under study. 
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2. MATERIALS AND METHODS 
2.1 TISSUE CULTURE MEDIA 
Two media formulations were used: - 
(i) High Antibiotic Medium 
Basal Medium Eagle's (Gibco, Paisley) supplemented with 20Ag/ml of 
amphotericin (Sigma) and 200gg/ml of gentamicin (Sigma) and 15mM Hepes 
(Gibco, Paisley). 
(ii) Growth Medium for tumour culture 
Ham's F12 medium (Gibco, Paisley) supplemented with: - 
2pg/ml amphotericin 
25 µg/ml gentamicin 
The following additions were made: - 
1) lOng/ml epidermal growth factor (Sigma) 
2) 10ug/ml insulin (Collaborative Research) 
3) 0.5pg/ml hydrocortisone (Sigma) 
4) 2.5µg/ml transferrin 
5) 2mM glutamine (Gibco) 
lml of each (1-5) added to each 100mis of Ham's F12 and 15% foetal calf 
serum (FCS - Biological Industries). 
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2.2 PREPARATION OF HUMAN TUMOUR SPECIMENS 
Biopsies from 117 patients with proven cervical carcinoma (1987-1989) were taken 
under anaesthesia immediately prior to radiotherapy. Parallel specimens were sent to the 
histopathology department at the Christie Hospital for grading. The grading of the 
tumours was assessed by two histopathologists for 75% of the specimens (n=88) and 
were graded into well, moderately and poorly differentiated carcinomas. The specimens 
were transported in a sterile container to the laboratory where the specimens were 
weighed after removing necrotic tissue and washed in high antibiotic medium. Each 
sample was placed in high antibiotic medium containing 0.5mg/ml of pronase 
(Boehringer Mannheim), collagenase type I (Sigma) and deoxyribonuclease (Sigma) for 
1.5 hours. 
The supernatant was then collected and placed on ice and further disaggregation was 
carried out with 0.05% trypsin (Worthington) for 0.5 hour. The tumour material was 
filtered using a 100µm nylon screen (Nybolt) and centrifuged for 10 minutes. If red 
blood cells were visible in the cell pellet these were lysed using 9mls of sterile double 
distilled water and the material was pipetted up and down twice to mix rapidly. One ml 
of x10 phosphate buffered saline (PBS) was then added followed by 10mis of culture 
medium. The material was centrifuged for 10 minutes and the pellet resuspended in 
culture medium. The cell suspension was filtered through a sterile 37µm nylon filter 
(Nybolt) to remove any remaining cell clumps [Fig. 2]. 
2.2.1 Multiplicity determinations 
A sample (100µl) was removed and 400µl of 0.4% Trypan Blue (Gibco, Paisley) was 
added. After 10 minutes viable, nucleated, trypan-blue excluding single cells, doublets 
and triplets as well as dead cells were counted on a haemocytometer. The number of 
viable cells, the viable cell yield, the multiplicity of the cell suspension and the percentage 
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of dead cells were calculated. 
M 
no. single cells + (no. doublets x 2) + (no. triplets x 3) 
no. single cells + no. doublets + no. triplets 
The multiplicity of the specimens was less than 1.05 for all the specimens except 7 
specimens. Multiplicity corrected counts were used in all experiments. 
2.3 SAMPLE IRRADIATION 
Irradiation of the cell suspensions was carried out at room temperature using a 137Cs 
gamma source with a dose rate of 4.2Gy per minute. After determining the viable cell 
density of the tumour cell suspension, lml was placed in test tubes (Falcon 2057) at a cell 
density of 1x106 cells/ml and 5x105 cells/ml for control tubes and irradiated at doses of 2 
and 3.5Gy. Where possible, doses up to IOGy were given, and the cell suspension 
irradiated at IOGy was used as a negative control. Again, the irradiated tubes were plated 
at more than one density if the tumour cell yield was large enough. The cell suspensions 
were plated without delay following irradiation. 
2.4 TUMOUR CULTURE 
2.4.1 Courtenay-Mills Soft Astar Clonogenic Assay 
The Courtenay-Mills soft agar clonogenic assay was used to determine the CFE of 
tumour cells from disaggregated tumours and the survival of those cells following 
radiation (Courtenay and Mills, 1978). 
Cell suspension (lml, and if specimen small, 0.5m1) at lOx the density required was 
placed into Falcon 2057 tubes. Rat red blood cells, 1ml of a1 in 8 dilution, was added to 
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FIG. 3 2057 TUBES CONTAINING COLONIES IN AGAR 
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the tumour cell suspension. Eight ml of 0.4% agar (stock agar was 5% Noble agar made 
up with double distilled water and autoclaved) was added to each 2057 tube. The 
medium was warmed to 37'C and the stock agar was held at 55'C and allowed to cool 
before adding to the medium. The 0.4% agar was pipetted up and down twice to mix the 
cells and lml aliquoted into each of 8 Falcon tubes ensuring that the tip of the pipette was 
at the bottom of the tube. No agar was placed on the sides of the tubes and no air 
bubbles were produced. The tubes were immediately placed on ice to set the agar. The 
tubes were placed into a 5% carbon dioxide, 5% oxygen, 90% nitrogen incubator with 
the caps of the tubes in the "loose" position. Occasionally, if the tumour specimen had a 
low cell yield, then 0.5ml of the cell suspension was placed in each tube and 4 replicates 
were set up for control and dose points. One ml of freshly warmed culture medium was 
added to each tube weekly and in the third week lml of medium was removed and lml 
added to each tube. After 4 weeks the tubes were removed from the incubator and 0.2ml 
of pre-warmed iodonitrotetrazolium violet (INT, Sigma) at 0.5mg/ml in double distilled 
water was added to each of the tubes which were then placed in a 20% oxygen incubator 
for 24 hours [Fig. 3]. 
2.4.2 Rat Red Blood Cells 
Blood was taken from August rats via cardiac puncture. Each rat was bled every 6-8 
weeks and approximately 2mls of blood was obtained per animal. The blood was 
processed as follows: - 
1. Centrifuge blood for 10 mins at 1500 rpm and remove supernatant. 
2. Add 5m1 PBS, centrifuge for 10 mins at 1500 rpm and remove supernatant. 
3. Add 5mls Ham's F12 + FCS, centrifuge at 2000 rpm and remove supernatant. 
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4. Place in a water bath at 44'C for 1 hour. 
5. Add Ham's F12 + 15% FCS to the original volume and then dilute this volume 
of blood 1 in 8 with F12 + 15% FCS. 
Diluted red blood cells were stored at 4'C for up to 2 weeks. 
2.4.3 Colony Counting 
Tubes were removed from incubation 24 hours after INT addition and the medium was 
suctioned off. 0.2m1 of 10% formol saline was added to each tube and the tubes were 
left overnight in a fume cupboard with the caps removed. The tubes [Fig. 3] were 
sometimes stored for a short time at 4'C but when colony counts were made on an 
experiment they were all counted on the same day. 
The agar from each tube was then placed on a slide, squashed with a coverslip and 
colonies were counted on a light microscope [see Fig. 4]. It was noted that some tumour 
colonies were adherent to the plastic test tube, made more noticeable with INT staining, 
and care was taken to ensure that these colonies were not omitted from the colony 
counting. Colonies greater than 50 cells (diameter> 60 um) were counted and the focus 
was continually moved up and down to ensure that all the colonies were counted. 
Colony counting was facilitated by using the low power and then checking the size of the 
colony using the high power (x400). A Kontron Mopp-Videoplan image analysis system 
was used to measure the diameters of the first 100 colonies for each tumour (using x100 
magnification) [Fig. 5]. Colony diameters were measured by using a Zeiss light 
microscope equipped with a drawing projection device which allowed superimposition of 
drawings to the microscope field of vision. By drawing around the tumour colonies on a 
measuring tablet, the diameters were obtained. This provided a check on the size of the 
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colonies counted and enabled statistics of colony size to be obtained [see Fig. 61. 
2.4.4 Frozen Tumour Storage 
Where specimen size allowed, aliquots of tumour cell suspension were stored in liquid 
nitrogen. Cells were frozen at a cell density of 106 cells/ml in culture medium in 10% 
dimethylsulphoxide (DMSO, Analar). The cells were stored in Nunc 2ml tubes and 
frozen slowly above liquid nitrogen for a minimum of 6 hours and then placed in liquid 
nitrogen. Twelve tumour biopsy specimens were stored in liquid nitrogen before 
processing and extra tumour biopsies received were also frozen in liquid nitrogen, if not 
processed immediately. The biopsy was cut into 3-4mm pieces and washed with high 
antibiotic medium. The tumour pieces were placed in high antibiotic medium with 10% 
DMSO and frozen in nitrogen. 
2.5 DIFFERENTIAL CELL COUNTS OF CYTOSPIN 
PREPARATIONS 
Cytospin preparations of each tumour cell suspension were made using 100u1 of the cell 
suspension at a concentration of approximately 105 cells/ml for each slide. Six to ten 
slides were prepared for each specimen. Two to four slides were stained immediately 
with the May Grunwald - Giemsa stain. The rest of the slides were wrapped in 
aluminium foil and stored in a freezer for immunohistochemical staining with monoclonal 
antibodies for human low molecular weight cytokeratins and human macrophages and the 
antibody for proliferating cells - Ki67. 
2.5.1 May Grunwald - Giemsa Staining 
Using air dried slides, the slides were flooded with neat May Grunwald staining solution 
(in methanol) and left for 2 minutes. The slides were then rinsed with tap water. The 
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FIG. 7 May Grunwald Giemsa stained cytospin 
of tumour cell suspension. 
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Giemsa stain was diluted 1.5 in 20 with Sorensen's phosphate buffer (1/15M Na2HPO4 
+ 1/15M KH2PO4 50: 50, pH 6.8). The slides were flooded for 18 minutes, rinsed in 
tap water, air dried and mounted. 
2.5.2 Counting 
The proportion of tumour cells, macrophages, lymphocytes and granulocytes for each 
tumour cell suspension was determined [Fig. 7]. After staining, 500 cells on 2-4 
cytospin slides were counted and scored as tumour cells, monocyte-macrophages, 
lymphocytes or granulocytes. Tumour cells were identified by their large size, their large 
euchromatic and irregular nuclei (which generally contained several large nucleoli) and 
their abundant, usually basophilic, cytoplasm. Macrophages were identified by their 
large size, eccentric, often lobulated nuclei, and abundant, usually highly vacuolated, 
cytoplasm. Lymphocytes were small, had a dense heterochromatic nuclear chromatic 
pattern and a thin rim of pale staining cytoplasm. Granulocytes were distinguished easily 
by their highly lobulated nucleus and cytoplasmic granules. The proportion of tumour 
cells in the cell suspension was also quantified by staining cytospins with the monoclonal 
antibody CKI (Dako) which stains the low molecular weight human cytokeratins 6 and 
18 (using the classification of Moll et al, 1982). If the tumour cells did not stain with 
CK1 then further immunostaining was carried out with the monoclonal CAM5.2 (Becton 
Dickinson) which stains the human cytokeratins 8,18 and 19 using the Moll 
classification (1982). The proportion of macrophages was also determined using a 
monoclonal antibody for human macrophage EBM 11 (Dako) due to the difficulty in 
distinguishing between tumour cells and macrophages in some specimens using 
morphological criteria alone. The antibody stains were carried out using the APAAP 
(alkaline phosphatase anti-alkaline phosphatase) technique. Between 300 and 500 cells 
were counted on 1 slide and the proportion of positive cells was expressed as a 
percentage of the total cells counted. 
(5 
2.5.3 APAAP Staining 
All staining was carried out in a humidified box at room temperature. The cytospins were 
fixed in acetone for 2 minutes and then transferred to Tris buffered saline (TBS). The 
slides were not allowed to dry out during the rest of the staining procedure as this has 
been shown to affect the quality of staining (Polak and Van Noorden, 1986). The 
primary mouse monoclonal was applied to the slide approximately 50 microlitres per 
slide. A1 in 100 dilution of CK1 and aI in 10 dilution of EBM11 were used. The 
CAM5.2 antibody was used at the dilution supplied. The monoclonal antibody which 
stains proliferating cells Ki67 (Dako) was used at a dilution of 1 in 50. The slides were 
incubated for 30 minutes and then washed in TBS for 5 minutes. The secondary 
antibody was applied -a rabbit anti-mouse immunoglobulin (Dako) diluted 1/20 in TBS 
with 20% normal human serum (heat inactivated by heating at 56'C for 30 mins). The 
slides were incubated for a further 30 minutes and washed in TBS before applying the 
APAAP complex (Dako) diluted 1 in 80 in TBS. Again a 30 minute incubation was 
carried out and the slides were washed in TBS. The applications of the second antibody 
and the APAAP complex were repeated for 15 minutes. This has been shown to enhance 
the staining when using this technique (Cordell et al, 1984). The substrate was applied 
for 15 minutes. The slides were then washed in tap water to terminate the reaction and 
counter-stained with Mayers Haematoxylin for 3-5 minues. The slides were mounted in 
the water soluble Apathy's mountant. 
Aliquots of the substrate used in the APAAP method were frozen in l Oml amounts. 
100mis of substrate were made up as follows: - 
20mg of naphthol AS MX phosphate (Sigma) dissolved in 2mls of dimethyl formamide 
and 98m1s of O. 1M Tris (BDH) buffer (pH 8.2) were added. 100 microlitres of 1M 
Levamisole (Sigma) were added (blocks the endogenous alkaline phosphatase). 
Immediately before use of the substrate 10mg of Fast Red salt (Sigma) was added and the 
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substrate was filtered through a 0.45 µm filter onto the slides. 
2.5.4 Double Staining using PAP and APAAP Techniaues 
To detect 2 antigens with mouse monoclonal antibodies, staining for one antigen was first 
revealed by an immunoperoxidase staining method followed by staining for the second 
antigen by immunoalkaline phosphatase. The cytospin preparations were fixed in acetone 
for 2 minutes and placed in TBS, pH 7.6. 
Immunoperoxidase 
The primary mouse monoclonal antibody was applied to each slide (CK1) for 30 
minutes. The slides were then washed in TBS for 5 minutes and incubated with rabbit 
anti-mouse immunoglobulin peroxidase conjugate at a dilution of 1 in 40 (Dako) for 30 
minutes. Normal human serum (1: 5 diluted with TBS) was added to block cross 
reactivity against human immunoglobulin. The slides were washed in TBS and incubated 
with swine anti-rabbit immunoglobulin conjugate (Dako) at a dilution of 1 in 50 for 30 
minutes and washed in TBS. The peroxidase substrate was then added (see below) to the 
slides for approximately 8 minutes. The slides were washed in TBS. 
The immunoalkaline phosphatase staining was then carried out as described above using 
Ki67 as the primary monoclonal antibody. The slides were mounted in an aqueous 
mounting medium. 
Immunoperoxidase Substrate 
10mg of diaminobenzidine 4110 (DAB, Sigma) was dissolved in 16.5mls of TBS. l7µ1 
of hydrogen peroxide (100 volume) was added and the substrate filtered onto the slides. 
51 
* 
411h 
!, 41 K"1" /" `ß ""C". "st .ý. ýr Pik 
1y 
y" ý 
'irk .., r"ý " . ". ý 'ý ri. Oý" ", 
4p 0_0 
X Art, 16 At*iF aw Of -CAP 
1% 
r 
9i 
-. 
4; 
ire. 
, i. 
" 
.., 
>41. 
'. I 
z 
ý) j'st ýý 1". 
p'I 
I ice` 
1 
,, 
i 
_ wº 
9r"ý. ý! +. º °o w '. S, ý is ', ý: * «ý 
r2 
. 9 
to -to I 
"% t"'"= 
4ýý",, 
try 1 "* :: ". '"i'ý "'ý. 'S1: 
W 
ý41S 
lop A 
jI, 
a so 
FIG. tt MEASUREMENT OF INTER-CAPILLARY DISTANCE 
ppý 
05 
Ko ý 
00o do 
5 
key: S= stroma K= keratin cap = capillary 
52 
2.6 TUMOUR VASCULARITY 
2.6.1 Intercanillarv Distance 
Five micron thick histological sections were cut from formalin-fixed and paraffin- 
embedded tumour biopsies from 107 consecutive patients with cervical carcinoma. The 
sections were stained using the Masson-Trichrome technique. Using this technique, the 
green-blue colour of the connective tissue and the elastic fibres in the vascular wall, red 
stained ery throcytes and haematoxylin stained tumour cell areas permitted a relatively 
easy distinction of the parenchymal, stromal and vascular elements. Adjacent 
microscopic visual fields (25-40) were scored on the entire section using x100 
magnification. Areas of gross necrosis and haemorrhage were avoided. An image 
analysis system Imagan II was used to measure the intercapillary distances. A grid in the 
eyepiece of the microscope was centred on a capillary vessel and a line was drawn to 
another capillary in each of 4 quadrants of the eyepeice, using a Leitz microscope 
equipped with a drawing projection device which allowed superimposition of drawings to 
the microscope field of vision [see Fig. 81. By drawing the lines between the capillaries 
on a magnetic tablet, the intercapillary distances were obtained. For each biopsy 100-160 
measurements for the intercapillary distance (ICD) were made. The computer enabled 
basic statistics for ICD to be obtained. 
In eleven tumour biopsies the distances between capillaries in the stromal bands were 
measured in addition to the ICD measured over the section in its entirety. 
2.6.2 Morphometry 
Morphometric analyses were made on each tumour biopsy. The tissue sections were 
scored by using a Chalkley grid in the eyepiece of a Leitz microscope. At least 40 high 
power fields were scored at a magnification of x400. The cells immediately to the right of 
53 
the 25 dots in the Chalkley grid were scored. Thus 1000 counts were made and the 
percentage volume components of parenchyma, stroma, vessels and necrosis were 
determined. For 10 tumours more than one biopsy was received on which a 
morphometric analysis could be carried out on each biopsy. 
2.7 STATISTICAL ANALYSES 
The statistical analyses were carried out on a MicroVAX 3600 computer system. The 
Minitab statistical software was used to test the correlation between quantitative variables 
by the establishment of linear regression coefficients and the Chi-Square test was used 
for the analyses of the frequency of qualitative variables. Analysis-of-variance was 
carried out with the SPSS statistical package. 
The radiation survival data from the tumour specimens were fitted to the linear quadratic 
equation using the program DRFIT on the MicroVAX. The program DRFIT is a 
comprehensive program for fitting survival curve data to a number of radiation survival 
models (Roberts, 1990). The data points are weighted by the inverse of their expected 
variances using the strategy of Gilbert (1969). 
2.8 CLINICAL DATA 
Patients with small volume stage IB or IIA disease were treated with intracavitary 
caesium alone with 2 insertions giving an A point dose of 67.5-75 Gy. For bulky stage 
IB disease or stage II disease and some stage III (no lymph node involvement 
demonstrated) patients received external beam irradiation to small-field, wedged 
inhomogeneous 3 week treatment (32.5 Gy to point B) followed by 2 intracavitary 
caesium insertions (A point dose of 50-60 Gy). If lymph node involvement was 
demonstrated patients received treatment by external beam to large hexagonal fields over 
4 weeks (40 Gy point A) supplemented by a single intracavitary insertion giving 
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32.5-37.5 Gy to A point (Hunter et al, 1986). 
The clinical data which were used to look at correlations with vascular parameters were 
on patients with minimum follow up time of 2 years. 
55 
FIG. 9 MAY GRUNWALD GIEMSA STAINED COLONY CELLS 
tl PV 
A 
k 
1. 
410 *4 jr .6 1& 
`' 
FIG. 10 CK1 STAINED COLONY CELLS 
4k 
. *I 
56 
a' 
3. VALIDATION OF THE ASSAY 
3.1 CHARACTERISATION OF COLONY CELLS 
Cytospin preparations were made from colonies grown from a number of the tumour 
specimens. The colonies were plucked from the agar at 4 weeks using a micropipette and 
disaggregated in 0.5% trypsin for 30 minutes with intermittent vortexing. The cytospin 
preparations were stored in a freezer until staining was carried out. Some of the colonies 
were also embedded in either 10% gelatin or tissue embedding medium (OCT, Tissue 
Tek) and frozen in liquid nitrogen until antibody staining was carried out. Frozen 
sections of the colonies were stained in addition to the cytospins. The cytospins were 
stained with the May Grunwald-Giemsa technique. The colony cells had large 
euchromatic and irregular nuclei and many had abundant cytoplasm, typical of tumour 
cells (Fig. 9) and had the same morphological characteristics as the cells in the original 
tumour cell suspensions. 
The colony cells were also stained using the APAAP immunohistochemical technique 
with CK1(DAKO) and CAM5.2 (Becton Dickinson), antibodies to low molecular weight 
cytokeratins. The colony cells stained positively with CK1 and/or CAM5.2 (Fig. 10) 
which confirmed that the colony cells were of malignant epithelial origin (Bobrow et al. 
1986). 
Tumour colonies from specimens V76 and V79 were cultured in repeat experiments for 
electron microscopy. The colonies were plucked from the agar (taking as little agar as 
possible) and washed in tris buffered saline. The pellets of colonies were taken to the 
electron microscopy department within 30 minutes and were prepared for transmission 
electron microscopy. Lower magnification pictures of the tumour colony cells (both from 
moderately differentiated tumours) showed cells which had the appearances of 
undifferentiated tumour cells. There were areas of close approximation between the cells, 
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but no desmosomes were seen, a common finding for poorly differentiated cells in 
culture. There were areas of extracellular matrix secretion, consistent with these colony 
cells arising from cells from the basal layer of the epidermis. Tonofilaments were not 
seen and would not be expected in undifferentiated cells. The cells had no features of 
macrophages. The appearances under EM were, therefore, those of undifferentiated 
tumour cells and when taken in conjunction with the results of the immunostaining 
provided proof that the cells which formed colonies were of malignant epithelial origin. 
3.2 COLONY SIZE 
The mean colony diameter measured for 57 tumours was 131±32 pm (± lsd) with a 
range of 77 to 255µm (Fig. 11). The minimum colony size counted was 60µm which 
ensured that colonies greater than 50 cells were counted. The size of 60µm was taken as 
the cut off for colonies of 50 or more cells and holds true for cells less than 11µm in 
diameter if the empirically-derived formula proposed by Meyskens et al (1984) is used. 
Cell diameters were measured on a number of the tumour specimens using a Coulter 
Multisizer System (Coulter Electronics, Luton) counter and cells greater than 11µm were 
not found (n=7, mean = 10.1, range 8.5 - 11µm). 
Using the formula of Meyskens et al (1984) 
2.4 (colony diameter)2.378 
no. of cells/colony = 
(cell diameter)2.8 
a 60um colony =l ljim cell diameter 
90µm colony = 16µm diameter 
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TABLE 4 COLONY SIZE REVIEW 
Reference Colony diameter 
Salmon et al, 1978 
Pavelic et al, 1980 
Kern et al, 1982 
Agrez et al, 1982 
Bertoncello et al, 1982 
Pathak et al, 1982 
Sandbach et al, 1982 
Sutherland et al, 1983 
>60µm 
260µm 
Williams et al, 1983 60-400µm 
Kirkels et al, 1983 >60-149µm 
Bertelson eta], 1984 >60µm 
Alley and Lieber, 1984 z60um 
Courtenay, 1984 
Salmon, 1984 
Fan et al, 1984 
Parker eta], 1984 
Hug eta], 1984 
Schiff and Shugar, 1984 
Hofman et al, 1984 
Gupta and Eberle, 1984 
Shoemaker eta], 1985 
Runge et al, 1985 
Endresen et al, 1985 
Eliason et al, 1985 
Walls and Twentyman, 1985 
Besch eta], 1986 
Von Hoff et at, 1986 
West and Sutherland, 1986 
Rofstad et al, 1987 
Page et al, 1988 
Ottestad et al, 1988 
Tveit eta], 1988 
Tveit eta], 1989 
>60um 
>30µm 
z60}im 
z75pm 
280µm 
2100µm 
>60µm 
80-100}im 
>100um 
z60um 
Z60µm 
2200µm 
z60um 
>100um 
>75jtm 
No. cells 
>40 
>30 
>20 
25-50 
>40 
>50 
z30 
20-40 
>50 
z40 
>20 
>40 
30-50 
30-40 
>30 
>50 
>50 
>50 
>50 
>50 
>30 
>30 
Assay 
H-S 
H-S 
H-S 
H-S 
B-M 
H-S 
H-S 
H-S 
H-S 
H-S 
H-S 
H-S 
C-M 
H-S 
modH-S 
H-S 
Double layer agar 
H-S 
C-M 
H-S 
modH-S 
H-S and C-M 
E 
Carney and C-M 
H-S 
H-S 
C-M 
C-M 
H-S 
C-M 
C-M 
C-M 
Key: H-S = Hamburger-Salmon, C-M = Courtenay-Mills, E= Eliason methyl cellulose 
system, B-M = Bradley-Metcalf 
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The number of cells in a 3-D system is difficult to quantify and therefore colony diameter 
provides a more precise measurement (Singletary et al, 1985). It is important to identify 
the proper colony size criterion to be used as the end point for quantitating cell survival. 
The shape of the radiation survival curves has been shown to be dependent on the size 
chosen to define a colony using the V79 cell line (Besch et al, 1986). From Table 4 it can 
be seen that a range of colony size and cell number has been used by many groups. 
Some tumour histologies have on average larger cells and require a greater minimum 
colony size eg. 100µm taken for melanoma by Tveit et al (1988). Very few studies 
comment on cell size though Agrez et al (1982) observed cell diameters of 14-18 microns 
in their series of solid tumours. Taking at least 50 cells per colony minimises errors from 
cell aggregates which may be introduced into the cell suspensions and is the minimum 
size for accurately assessing cell radiation survival. 
3.3 LINEARITY OF COLONY FORMATION 
It is important to establish a linear relationship between the number of colonies formed 
and the concentration of cells plated in clonogenic assays. This has been demonstrated in 
some studies (Hamburger, 1987; Pavelic et al, 1980) but not in others (Eliason et al, 
1985; Page et al, 1988; Meyskens et al, 1983). In this work linearity was demonstrated 
with a good correlation between the number of cells plated and colonies formed , 
, in 
55 specimens. Enough cells were obtained in 19 tumour specimens to plate out 
more than one density for the irradiated specimens (at 2Gy) to demonstrate linearity of 
colony formation in irradiated specimens also (Fig. 12). 
3.4 RADIATION SURVIVAL CURVES 
Clonogenic assays have also been criticised in the past due to the lack of evidence of 
survival curves after exposure to ionising radiation (Selby et al. 1983; Meyskens, 1983). 
The presence of clumps has been shown to produce a plateau on the radiation survival 
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curves (Meyskens, 1983; Rockwell, 1985). Survival curves were produced where 
enough cells were obtained from specimens, with irradiation carried out at doses from 1 
to 7 Gy, and irradiation at 10 Gy used as a negative control to check that cell clumps were 
not present in the original cell suspensions. As the colony forming efficiencies are low 
very few or no colonies would be seen in the 10 Gy irradiated tubes. The shapes of the 
survival curves established in this work are similar to those of survival curves obtained 
from tumour cell lines established in monolayer culture. The linear quadratic model was 
fitted to the curves using the DRFIT program (Chapter 2) and a wide variation in the 
alpha values was obtained 0.21-0.91 Gy 1 (Fig. 13). The survival curves plotted in 
figure 13 were based on 2-4 experiments and error bars have been omitted for clarity, 
though the errors have been listed in Appendix 4. 
Surviving fraction at 3.5 Gy was determined for 39 specimens giving a mean value of 
0.23 ± 0.14 (±1 sd). In all cases the SF3.5 value was lower than the SF2 value. 
3.5 SURVIVING FRACTION AT 2GY FOR DIFFERENT TUMOUR 
HISTOLOGIES 
As part of the validation of the assay colorectal tumours and lymphomas were processed 
using the Courtenay-Mills soft agar assay to determine SF2 values for these tumour types 
and to look for differences in the values obtained. SF2 was obtained for 19 colorectal 
tumours and 7 lymphomas (Table 5). The mean SF2 for the colorectal tumours was 
0.60±0.17±0.04 (±1 sd ±1 sem) with a range of 0.23 - 0.84. The mean SF2 for the 
lymphomas was 0.30±0.05±0.02 (±1 sd ±1 sem) with a range of 0.22 - 0.36 (Fig. 14). 
A two sample t-test was carried out between the means of the cervix tumours and the 
colorectal tumours, t=3.27, p=0.003, DF=29, showing that the difference between the 
means of the two tumour groups was highly significant. Similarly, a t-test showed a 
significant difference between the mean SF2 of the lymphomas and the cervix tumours 
(t=4.82, p=0.0001, DF=22). This contrasts with the findings of Rofstad et al 
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TABLES SF2 FOR DIFFERENT TUMOUR HISTOLOGIES 
Colorectal specimens (n= 19) 
SF2 values 
Lymphomas (n=7) 
SF2 values 
C13 0.72 L2 0.36 
C14 0.56 13 0.22 
C16 0.7 L4 0.27 
C17 0.56 L7 0.33 
C18 0.72 L9 0.35 
C19 0.61 L10 0.24 
C24 0.79 L14 0.34 
C26 0.62 
C27 0.71 Ave SF2 = 0.3±0.05±0.02 
C29 0.56 (±l sd ±1 SEM) 
C34 0.29 median 0.33 
C35 0.6 (0.22 - 0.36) 
C36 0.75 
C38 0.83 t-test - between means of 
C40 0.23 cervix tumours and 
C48 0.44 lymphomas 
C53 0.39 t=4.82, p=0.0001, 
C54 0.43 Df = 22 
C60 0.84 
Ave SF2 = 0.597 median 0.61 
= 0.6±0.17±0.04 
(±1 SD ±1 SEM) 
(0.23 - 0.84) 
t-test - between means of cervix and 
colorectal tumours 
t=-3.27, p=0.0028 
Df = 29 
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(1987) who carried out SF2 determinations on 7 different tumour types and did not 
demonstrate a significant difference between the mean SF2 values of the 7 tumour groups 
using the same assay. Within each tumour group there was a wide range of SF2 values 
obtained, though the mean for 8 cervix tumours was lower (0.30) compared to 0.44 for 
77 cervical carcinomas in this work. In the analysis of the published data by Malaise et al 
(1989) cells were consistently more sensitive when tested by clonogenic assay and when 
compared with colony formation for established cell lines (Suit et al, 1989). However, 
the mean SF2 for the groups of primary tumours determined by the Courtenay-Mills 
assay in this study are similar to the mean values obtained for cell lines derived from 
tumours from these classes (West et al, 1989; Suit et al, 1989). Average values were 
0.49 ± 0.07 and 0.43 ± 0.06 (±1 SEM) for colorectal and cervix for published values 
(West et al, 1989) and 0.34 for 7 lymphoma cell lines (Fertil and Malaise, 1985). Brock 
et al (1989) found that the SF2 values for head and neck tumours, obtained using the 
CAM assay, were more sensitive than melanomas and lung adenocarcinomas. The 
average value for 72 squamous cell carcinoma cultures was 0.33. The reasons for these 
differences in the SF2 values obtained by the different groups, in particular between the 
values obtained with this assay and the work of Rofstad and colleagues using the same 
assay, are not clear. The numbers of cervix tumours in the Oslo study was only 8 and it 
is likely that some tumour selection occurred. In addition the plating efficiencies of the 
Oslo group were higher, 0.4 - 2.1 % for the cervix tumours. Culture conditions have 
been shown to affect the radiosensitivity of cells (West and Sutherland, 1986). The SF2 
values obtained from in vitro assays should not be expected to reflect simply and directly 
radiation sensitivity in vivo (Suit et al, 1989). It may be that the relative ranking of 
radiosensitivity, as measured by the SF2, will prove to be of importance within one 
laboratory, rather than the absolute value. 
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4. REPRODUCIBILITY OF THE ASSAY AND 
INVESTIGATION OF TUMOUR HETEROGENEITY 
4.1 RESULTS 
Values for SF2 were obtained for 77 cervix tumours, the mean value being 0.44 (SD 
0.19) with a range of 0.14 - 0.97 (Fig. 15). The sampling errors of the cell counts, made 
on the tumour cell suspensions prior to plating, were of the order of 7% or less as more 
than 200 cells were counted for the majority of specimens. In order to eliminate the 
errors due to small numbers, the experimental errors were calculated for those 
experiments where the CFE was high ie. >100 colonies per tube. The mean 
intra-experimental coefficient of variation was 19% (7 - 35%, n= 12). The mean 
coefficient of variation for repeat experiments was 11% based on 6 tumour specimens 
with 2-4 experiments. 
Analysis-of-variance techniques were used to determine the significance of the inter- and 
intra-tumour variation, using both one-way and nested designs. Duncan's Multiple 
Range Test was used to determine which pairs of tumours were significantly different 
from each other. The maximum number of specimens which could be analysed using the 
Multiple Range Test with the statistical package used was 50. A logarithmic 
transformation was applied to the CFE data in order to achieve a more normal 
distribution. A significance level of p <0.05 was used throughout. Analysis of variance 
showed there were no significant differences in the SF2 values obtained between repeat 
experiments. Using frozen tumour cell suspensions from 23 specimens 2-4 repeat 
experiments were carried out with 34 repeat experiments in total. Six repeat experiments 
were performed using tumour biopsies which had been stored in liquid nitrogen (Fig. 
16). Interestingly, there were significant differences in the CFEs of the repeat 
experiments (p <0.001). Repeat experiments on the 3 specimens with low SF2 values 
(V26, V33 and V38 shown in Fig. 16) were carried out with a6 month interval and were 
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processed along with other specimens giving higher SF2 values ie. these low SF2 values 
were reproducible. In addition, biopsies from four tumours processed by two different 
experimentors gave SF2 values which were not significantly different (p = 0.1; V26 and 
V33 Fig. 16, V 17 and V 18 data not shown). 
The overall CV for the SF2 values obtained from the different tumours was 42%. There 
were highly significant differences in SF2 values obtained for the different tumours (p 
<0.001). In order to evaluate intra-tumour heterogeneity, eighteen "split" tumour 
experiments were carried out. Five tumours showed no growth in either culture but two 
SF2 values were obtained in thirteen tumours (Table 7). The differences in the CFEs of 
the two tumour halves processed were highly significant (p <0.001). Nonetheless, the 
analysis of variance showed that there were no significant differences between the SF2 
values obtained from each tumour part. However, the number of tumours evaluated in 
this way is small and larger numbers will be needed before firm conclusions regarding 
SF2 can be made. 
In order to illustrate the discriminatory power of the assay, two further statistical analyses 
were performed. A Duncan's Multiple Range Test (Fig. 17), shows which pairs of 
tumours had significantly different SF2 values. Most values below about 0.4 are 
significantly different from those above about 0.6. Evaluating the 95% confidence limits 
for each mean (Fig. 18), shows the proportions with each SF2 value that are significantly 
different from the mean, given the variability in the errors of the SF2 values. 
4.2 DISCUSSION 
Potential limitations of any proposed predictive assay need to be explored prior to 
evaluation of associations with clinical outcome. It is important to determine 1) the 
adequacy of the assay, 2) sampling errors, resolution and reproducibility, 3) 
intra-tumour heterogeneity and 4) inter-tumour (patient) variation, which is the aim of 
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the assessment. A large range of SF2 values will increase the predictive accuracy while 
large assay errors reduce it. 
Validation of the assay used in this work (see Chapter 3) was established by 
demonstrating good linearity between the cells plated and colonies formed. An image 
analysis system was used to aid colony counting and ensure that only colonies greater 
than 60 microns in diameter were counted. 
The freezing of cells in liquid nitrogen has been demonstrated previously not to alter the 
radiosensitivity of cells (Rofstad et al, 1987; Selby and Steel, 1981) and these results 
support this. Storage in nitrogen does however affect the colony forming efficiency and 
for many specimens the CFE increased with repeat experiments. This may be due to the 
plating of increased numbers of cells with the non-viable cells exerting a feeder cell 
effect. No statistical difference between the SF2 values obtained from repeat experiments 
was seen. The mean intra-experimental coefficient of variation for the assay was 19% 
and the CV for repeat experiments was 11%. This compares with 9% for the repeat 
assays on the same tumour cell suspension with the adhesive tumour cell assay used by 
the group in Houston (Brock et al. 1989). The experimental errors varied amongst 
tumour specimens and the errors tended to be higher in the experiments where the CFE 
was low. Repeatability, as measured by the coefficient of variation, was investigated in 
reported series using clonogenic assays (Table 6). 
Few series report their intra-tumour and inter-assay errors Coefficients of variation were 
calculated from radiation survival curves giving individual dose points and inter 
experimental CVs were calculated when repeat experiment data was presented. The assay 
errors in this work compare favourably. 
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TABLE 6 
INTER- AND INTRA-EXPERIMENTAL COEFFICIENT OF 
VARIATIONS OBTAINED FOR SF2 AND CFE 
(Given in text or read from radiation survival curves) 
Assay 
on plastic 
H-S 
H-S 
H-S 
C-M 
on plastic 
H-S 
C-M 
inter-expt intra-expt Reference 
19-25% for 6 expts 
with cervix line for 
SF2 
12% for SF2 
25% 5 expts cervix 
line for SF2 
on plastic CV=21-25% 2 expts 
with ovarian cell 
line SF2 
*CAM CV=9% for SF2 
soft agar CV=12% 
colony assay 
* population growth assay. 
r 
SD of dose points Puck and 
10-25% of the mean Marcus, 1957 
Mean CV=22% Hamburger et 
for PE al, 1978 
5-50% CV for PE Shoemaker et 
on 100 expts. al, 1985 
3-50% mean CV=14% Bizzari and 
Mackillop, 1985 
West (unpub) 
1986 
9-55% for SF2 on Duchesne 
5 expts et al, 1986 
Rofstad and 
Sutherland, 
1988 
Brock et al, 
1989 
Malaise et 
al, 1989 
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The wide range of SF2 values is similar to that obtained by others investigating head and 
neck tumours (Brock et al, 1989) and reflects the considerable inter-tumour heterogeneity 
to be found within a single tumour class. We have shown that this variation in the values 
is not due to intra-tumour heterogeneity. From these results there is evidence for one 
continuous distribution of SF2 values (Fig. 15). In the final multivariate analysis which 
includes patients follow up data it may be possible to identify the radioresistant and 
radiosensitive tumours, although it is unlikely that radiosensitivity alone will be used in 
predicting outcome of treatment. The range of values for a potential preditive test has to 
be large enough to allow discrimination between the different tumours and be large in 
relation to errors associated with the assay. The range of values for SF2 lends support to 
the concept that SF2 may be a useful prognostic test. The distribution of SF2 and the 
assay errors suggest that it will only be possible to distinguish between radiosensitive and 
more resistant tumours if the SF2 values for the former are below 0.4 and the latter are 
above about 0.6 or 0.7. A theoretical study investigating the effect of inter-patient 
variation on the accuracy of predictive assays showed that those based on intrinsic 
tumour cell radiosensitivity are more likely to correlate with clinical outcome than assays 
of tumour doubling time, hypoxic fraction or clonogen content (Tucker and Thames, 
1989). 
Heterogeneity within tumours is another potential limitation to radiosensitvity testing. 
The existence of cell subpopulations within solid tumours is well described (Heppner and 
Miller, 1989; Mackillop and Dotsikas, 1988). Heterogeneity in the structure and 
organisation of cancer tissues is also important, and one small biopsy may not represent 
the tumour tissue as a whole (Heppner, 1984). Heterogeneity of human tumours has 
been demonstrated by their DNA content (Tveit et al, 1985). In a large series of cervical 
tumours, flow cytometry has been used to demonstrate considerable intra-tumour 
heterogeneity of DNA content, as part of an investigation into the differential 
radioresponsiveness of this tumour class (Dyson et al, 1987). Intra-tumour heterogeneity 
to drug treatment has also been shown, both in vitro and in vivo (Leith and Dexter, 1986; 
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Tofilon et al, 1986), and had been demonstrated in studies comparing responses of 
metastases and primary tumour (Schlag and Schremi, 1982). In a study on intra-tumour 
heterogeneity of chemosensitivity of 8 primary tumour cultures, 50% discordant results 
of sensitivity were obtained, using a clonogenic assay, from the two halves of the 
biopsies processed independently (Kern et al, 1984), though the numbers were small and 
different tumour types were used. Relatively few investigations have been made on intra 
tumour heterogeneity of radiation sensitivity. Leith and colleagues (1982) showed 
significant differences in the intrinsic radiosensitivities of subpopulations in a human 
colon carcinoma cell line (DLD-1) and a lung carcinoma cell line (LX1). 
Heterogeneity of intra-tumour radiosensitivity of primary human cultures have been 
investigated indirectly by Tofilon et al (1989) using the adhesive tumour cell assay and 
assays of cisplatinum induced SCE. Subpopulations, identified by cisplatinum induced 
SCE, were found to have differing radiosensitivities. Differences in radiation survival 
were detected in 50% of cultures that were predicted to have heterogenous 
radiosensitivity in the SCE assay. 
Clearly there is evidence for the existence of sub-populations within tumours and 
heterogeneity of intra-tumour sensitivity to therapy. However, the results presented here 
suggest that intra-tumour heterogeneity is not a limitation to the use of the 
Courtenay-Mills assay for radiosensitivity testing for cervical tumours, ie. a single biopsy 
is representative of the tumour. Our results investigating the possible variation in the SF2 
measurements made from different sites in one tumour using the clonogenic assay did not 
demonstrate any significant differences. The SF2 value obtained from a single biopsy is 
likely to be an average value and to reflect the response of the more sensitive cells within 
a tumour. If the sensitivity of these cells dominates in the radioresponsiveness of the 
tumour then radiosensitivity testing will be predictive. 
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TABLE 7 
TUMOUR HETEROGENEITY 
18 tumour samples processed as 2 separate cell suspensions. 
No growth from 2 cell suspensions in 5 tumours. 
Specimen No. Sample A Sample B 
CFE ±I SEM SF2 ±1 SEM CFE ±1 SEM SF2 ±1 SEM 
33 0.41±. 03 0.13±. 04 0.09 ± . 007 0.19±. 03 
38 0.023±. 002 0.31 ±. 04 0.016 ± . 007 0.31 ±. 06 
60 0.21±. 05 0.34 ± . 06 0.11±. O1 0.53 ± . 08 
61 0.06 ± . 02 0.35 ± . 03 0.22 ± . 01 0.72 ± . 05 
65 0.21 ± . 03 0.56 ± . 18 0.17 ± . 05 0.35 ± . 22 
71 0.13 ± . 08 0.31 ± . 15 0.32 ± . 07 0.36 ± . 01 
74 0.02 ± . 005 0.37 ± . 06 0.06 ± . 007 0.42 ± . 06 
76 1.09 ± . 07 0.68 ± .1 1.17 ± . 08 0.58 ± . 04 
81 0.22 ± . 03 0.46 ± . 09 0.06 ± . 006 0.47 ± . 06 
84 0.11 ± . 01 0.46 ± . 08 0.23 ± . 02 0.40 ± .1 
87 0.26 ± . 07 0.53 ± . 28 0.16 ± . 03 0.70 ± . 25 
88 0.22 ± . 04 0.44 ± . 16 0.10 ± . 02 0.79 ± . 18 
89 0.23 ± . 04 0.68 ± .3 0.16 ± . 03 0.70±. 15 
Reproduced in part from West et al, 1989. 
7b 
S. EVALUATION OF IN VITRO CLONOGENIC GROWTH 
5.1 RESULTS 
One hundred and seventeen tumours (110 squamous cell carcinomas and 7 
adenocarcinomas) were processed with successful growth in 84 (72%). The mean 
colony forming efficiency was 0.18% with a range from 0.003 to 4.28%, a normal 
distribution and a standard deviation of 0.49% for 80 squamous cell tumours (Figs 19 
and 20). The mean CFE for 4 adenocarcinomas was 0.18 ± 0.12%. These CFEs were 
based on total viable nucleated cell counts. The mean CFE, corrected for the proportion 
of tumour cells in the suspensions, was 0.38 ± 0.64% (± 1 SD). The mean proportion 
of tumour cells in the suspensions was 44.5 ± 14.5% (±1 SD) with a range of 10 - 85%. 
There were 3 infections out of the 117 specimens (2%). A count of more than 10 
colonies per tube was chosen as an arbitrary cut off point for in vitro growth. Repeat 
experiments were carried out on tumour cell suspensions (n - 34) and biopsies (n = 6) 
which had been stored in liquid nitrogen. The CFEs of the repeat experiments were 
higher than with the first experiments and these differences have been shown to be highly 
significant (Chapter 4). The CFE's of fresh specimens only have been used in the 
analysis of the results. 
Tumour differentiation was assessed in 75% (n = 88) of the specimens by the two 
histopathologists at the Christie Hospital. A further 19 tumour biopsies had been 
assigned tumour grade by the pathologists at the referring hospital. There were 20 well 
differentiated tumours, 48 moderately differentiated and 39 poorly differentiated tumours. 
The biopsies were from patients with all tumour stages, with the majority being either 
Stage I or II (Table 2). The ages of the patients in this series ranged from 26 to 90 with a 
median age of 50 years. 
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TABLE 8 TUMOUR STAGE 
STAGE I II III IV 
NO 37 39 12 5 
A chi-square test was performed and showed no relationship between tumour 
differentiation and CFE. The CFE was divided into two groups, less than or greater than 
the median corrected CFE of 0.14% (Table 3). These analyses were carried out on CFEs 
TABLE 9 TUMOUR GRADE AND CFE 
CFE 
<0.14% >0.14% 
DIFF WELL 13 7 
MOD 24 24 
POOR 25 14 
62 45 
chi-square = 2.25,2 d. f, p=0.32 
corrected for the proportion of tumour cells in the cell suspensions, although when the 
CFEs, based on total viable cell counts, were analysed there was no relationship 
demonstrated (chi-square = 0.75,2 d. f., p=0.75). In view of the subjective nature of 
the grading of tumours, the specimens which were graded by one pathologist (n = 52) 
were analysed separately and again no relationship between CFE and tumour grade could 
be demonstrated (Table 4). 
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TABLE 10 TUMOUR GRADE AND UNCORRECTED CFE 
median CFE (uncorrected) = 0.06%, one histopathologist 
CFE 
<0.06% >0.06% 
DIFF WELL 54 
MOD 13 11 
POOR 8 11 
26 26 
chi-square = 0.75,2 d. f, p=0.75 
The tumours which grew in culture were investigated to see if this group was different 
from the tumours which did not grow in culture using a 2x2 contingency table and a 
chi-square test (Table 5). Interestingly, when a chi-square test was performed with fewer 
TABLE 11 TUMOUR GRADE AND IN VITRO GROWTH 
No growth good growth (CFE >0.14%) 
WELL 57 
MOD 11 24 
POOR 9 14 
25 45 
chi-square = 0.58,2 d. f, p=0.7 
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tumours (Table 6) the chi-square test showed that the tumour grade did appear to be 
significantly related to CFE with p=0.02. The CFE was neither related to tumour stage 
(r =0.02) nor patient age (r = 0.12). 
The CFE was not correlated with SF2, r= -0.06 (n = 77). In figure 21 results for 3 
tumours are shown for which more than 4 repeat SF2 determinations were obtained. 
Correlation coefficients were 0.62, -0.81 and 0.03 for samples V61, V76 and V32 
respectively. Regression analyses, weighting by the inverse variance of CFE, gave r 
values for V61 and V76 of 0.4 (p = 0.44) and -0.64 (p = 0.12) respectively. 
TABLE 12 EARLY ANALYSIS OF TUMOUR GRADE AND CFE 
CFE 
<0.145% >O. 145% 
WELL 13 1 
MOD 17 17 
POOR 17 9 
47 27 
chi-square = 7.92,2 d. f, p=0.02, taking the median CFE of 0.145% 
as the cut off between poor and good growth. 
5.2 DISCUSSION 
Relatively few series are reported to have solely concentrated on the primary clonogenic 
culture of human cervical carcinoma. Williams et al (1983) grew 1 out of 29 specimens, 
Parker and co-workers (1984) reported an 88% success rate with 76 tumours and Von 
Hoff (1990) reported 20% success with primary cervix tumours. No CFEs were given 
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in the study by Parker et al (1984) nor Williams et al (1984). The 73% success rate 
reported here compares favourably with these. In addition by using the Courtenay-Mills 
soft agar assay high CFEs have been obtained which is in agreement with the finding that 
higher CFEs can be obtained with the Courtenay-Mills assay when compared with the 
Hamburger-Salmon assay (Endresen et al, 1985; Ottestad et al, 1988). 
Twenty eight per cent of the biopsy specimens received did not grow in vitro (< 10 
colonies per tube). This figure agrees well with values published in the literature for 
other large series which have looked at different tumour classes (Ottestad et al, 1988; 
Tveit et al. 1989). Those tumours that do not grow well in culture may be less 
aggressive in their clinical behaviour (Hug, 1985; Moezzi, 1986; Flentje, 1987). 
However there are several reasons for not assuming that the growth of cancer cells in 
vitro should reflect the biological aggressiveness of a tumour and the clinical course of 
the disease (Ottestad et al, 1989). Good in vitro growth may express capacity for growth 
under specific culture conditions and does not necessarily reflect the intrinsic growth 
capacity of cells. There is inevitably selection of populations in colony forming assays. 
The results obtained to date by independent research groups have been contradictory 
(Table 3 in section 1.3.4) possibly because of varying tumour histologies and relatively 
small numbers of patients (Nomura et al, 1989). 
This study failed to demonstrate any correlation between in vitro colony growth and 
tumour differentiation. Although it is noteworthy that analysis of the first 74 specimens 
using the chi-square showed a positive correlation (p = <0.05). This illustrates the 
importance of carrying out studies on large numbers of samples. Adding these results to 
those listed in Table 3 further contributes to the contradictory nature of the results 
obtained. There is no obvious trend. Five studies have shown a lack of correlation 
whilst two have demonstrated a correlation. Small sample size is a criticism of some 
studies yet of the two largest studies, one showed a correlation and the other did not. 
Obviously there may be differences between tumour types. However the largest number 
86 
of studies have been carried out on breast cancer and two showed the existence of a 
correlation, whilst three did not. 
It should be noted that tumour grading is not precise. A major criticism is the issue of 
inter-observer reproducibility, reflected in inter-series comparisons (Contesso et al. 
1989). In addition there are difficulties in defining grade using classifications of Broder 
or Reagan and Wentz (Goellner, 1976) and these may be added to sampling errors from 
the biopsies (Gundersen et al, 1974). Inter-observer reproducibility, use of different 
grading systems and small sample size may obscure the relationship between 
differentiation and in vitro growth in many series. Although more than one pathologist 
graded the specimens in the series reported here, when the 52 tumours graded by one 
pathologist were analysed, no relationship between tumour grade and CFE was 
demonstrated. It may be that in vitro clonogenicity, when carefully carried out under 
controlled conditions, it is a more objective measurement than grade. 
This work shows no correlation between CFE and radiosensitivity as measured by SF2. 
Brenner et al (1987) reported a strong correlation between radiation sensitivity and plating 
efficiency for 2 cell lines. Bristow et al (1990) showed that for a panel of murine tumour 
cell lines, higher values of SF2 may be associated with those cell lines that have higher 
plating efficiencies in vitro. However the results from this study are in agreement with 
the findings of Fertil and Malaise (1981) who found no relationship between in vitro 
radiosensitivity and CFE for human tumour cell lines (n = 365). Technical artefacts such 
as minimum colony size counted (Nias and Fox, 1968) and culture conditions (West and 
Sutherland, 1986) may alter radiosensitivity and may be responsible for these 
differences. 
Although these results have not shown a correlation between clonogenic ability and 
grade, grade itself is not generally accepted as predictive of outcome in carcinoma of the 
cervix (Ng and Atkin, 1973; Goellner, 1976; Van Nagell, 1977; Prempree, 1983). The 
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lack of correlation seen between CFE and other prognostic factors (eg. stage) may reflect 
the independence of CFE as a potential predictive factor. This is suggested also by the 
lack of correlation with other biological endpoints evaluated. Therefore these results do 
not rule out the possibility that in time CFE may prove to be a prognostic indicator for 
patient outcome. 
a 
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6. ASSOCIATED STUDIES 
6.1 TUMOUR VASCULARITY 
6.1.1. Vascularity results 
Of the 99 biopsies received for paraffin embedding, vascularity was assessed in 87 
(88%). The remaining tumour biopsies were either too small, of too poor quality to be 
able to score (n = 10) or contained insufficient tumour tissue (n=2). The mean inter 
capillary distance (ICD) was 240 microns with a standard deviation of 37 microns 
(median = 239 microns), a range of 131-333 microns [Fig. 22] and a mean intra-tumour 
CV of 38% (n = 72). A normal distribution was obtained and the overall coefficient of 
variation between the tumours was 15%. The mean ICD measured in the stromal bands 
of 11 tumours was 139 ± 26 microns (± 1SD), with an intra-tumour CV of 18%. 
There was no correlation between ICD and tumour grade, r=0.05 (tumour grade: well 
diff. = 18, moderately diff. = 39, poorly diff. = 28); stage, r=0.12 (Stage I, n= 36; 
Stage II, n= 30; Stage III, n= 13; Stage IV, n= 7) or radiosensitivity, as measured by 
SF2, r=0.05 (n = 57). When the mean ICD for Stage I tumours (231 ± 36pm) was 
compared with the mean ICD for pooled Stages II, III and IV tumours (247 ± 38}im) 
using a t-test, the difference was approaching significance, t=1.88, p=0.06, DF = 71. 
The morphometric analyses gave a mean proportion of vessels for the tumours of 2.68% 
t 1.64% (± 1 SD) with a range of 0.6 - 11% and a CV of 61% between individual 
tumours [Fig. 231. The mean proportion of parenchymal cells was 61.3 ± 17.9% (±1 
SD) and the mean stromal proportion was 27.5 ± 14%. There was no correlation 
between the proportion of vessels and tumour grade, r= -0.1, the stage of disease r= 
0.04 or with SF2, r= -0.03. Morphometry was performed on 10 tumours where two 
biopsies were received. A two sample t-test was carried out on the mean percentage of 
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ICD (microns) 
vessels obtained on each biopsy (T = 0.48, p=0.64, DF = 12) which suggested that the 
values were not significantly different from each biopsy. The mean ICD for 7 
adenocarcinomas was 204 ± 42 microns (± 1 SD) and a range of 130.5 - 257 microns. 
The mean percentage of vessels in these adenocarcinomas was 3.4 ± 1.87% (± 1 SD). 
This mean value of ICD of adenocarcinomas was not shown to be significantly different 
from the value for squamous cell tumours (t = -2.33, p=0.06, DF = 6). 
Clinical data was obtained from 35 patients with at least 2 years follow up after 
radiotherapy (Table 14). The mean ICD of the 17 patients who were disease free at 2 
years was 235 ± 32 microns (± 1 SD), with a median of 232 microns and a range of 185 
- 299 microns. The mean ICD of 18 patients who had died from recurrent disease or 
who had recurrent disease at two years (pelvic recurrence or pelvic disease with 
metastases) was 244 ± 37 microns, with a median of 240 microns and a range of 193 - 
333 microns. A two sample t-test was performed which failed to demonstrate a 
significant difference between the means of the two groups (t = 0.74, p=0.47, DF = 
32). Similarly no significant difference was seen between the mean percentage of vessels 
in the group which was disease free (mean = 2.42 ± 1.5%, median 2%) and the group of 
patients who had died or had recurrent disease (mean = 2.16 ± 1.1%, median 1.8%) 
with at value of -0.6, p=0.55 and DF = 29. 
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6.1.2 Vascularity discussion 
TABLE 13 STUDIES ON VASCULARITY IN HUMAN TUMOURS 
TUMOUR STAGE NO. METHOD 
TYPE 
Cervix I-IV 105 Colpophotography 
Cervix IB & IIA 45 Morphometry 
Cervix IIB & III 36 Alkaline phos. 
technique 
Nasopharynx III & IV 25 Morphometry 
CONCLUSION REFERENCE 
>400pm ICD 51% recur Kolstad 
<400µm ICD 16.7% 1968 
local recurrence 
Survival> 5 years 28.9% Sirackaet al 
vessels in stroma, <5 yrs. 1982 
10.5% vessels in stroma 
Mean ICD = 322µm recur Awwad et al 
at 2 yrs, mean ICD - 291µm 1986 
disease free 
Capillary density correl. Delides et al 
with survival time 1988 
Oral SCC T2&T3 26 Anti-factorVff 
stain 
Cervix IB, IIA & III 95 Morphometry 
Cervix IB, II & III 95 Morphometry 
Median vessel tumour cell Lauk et al 
dist - 105µm for local 1989 
control and 75µm in local 
recurrence 
High vessel density - Sirackyet al 
survival >5 yrs, low vessel 1988 
density - survival <5 yrs 
Vessel density - 25.6% >5 yr Revesz et al 
survival, vessel density - 1989 
10.6% <5 yr survival 
The survival time in months was calculated for the patients with at least two years follow 
up from their radiotherapy (excluding those with metastases with no evidence of local 
recurrence in the pelvis, n= 29). The mean survival time was 20 months, median 23 
months and a range of 5- 30 months. There was no correlation between the survival 
time and ICD (r = -0.008) nor with the percentage of vessels (r - 0.08). 
The measurements obtained in this study are similar to those reported by others. Awwad 
and colleagues (1986) obtained a mean ICD of 304µm with an intra-tumour CV ranging 
from 12 - 32% and an inter-tumour CV of 10%. Revesz and Siracka (1984) reported 
proportions of parenchymal and stromal components of around 70 and 30% respectively 
and a wide variation (7-22%) in the mean vascular density within a tumour. Although 
Kolstad (1968) suggested that adenocarcinomas should be investigated separately from 
squamous tumours because of different vasculature patterns in these two different 
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histologies, no difference was shown between adenocarcinomas and squamous tumours 
in this study. 
It is important to assess the intra tumour variation of vascularity in addition to asessing 
the variation between tumours. Surgically removed specimens (Stage IB, n= 4) were 
looked at by Siracka et al (1988). They found that the variance in vascularity within 
tumours was less than that between tumours, although considerable variation in 
vasculature within different regions of the same specimen was demonstrated. The 
variation in vascular density was assessed morphometrically by Revesz et al (1989) in 14 
sugically removed specimens of stage II tumours. A wide variation in vasculature of each 
tumour was demonstrated but the inter tumour variation was greater than the intra-tumour 
variation, although the tumours from one of the centres were all moderately to highly 
differentiated tumours and no poorly differentiated tumours were studied. The results 
obtained in this work are in agreement with these studies; where 10 tumours with two 
biopsies showed a wide variation in percentage of vessels between biopsies 0.6 - 5.8%, 
but these differences were not significantly different within each specimen. 
No correlation was demonstrated between ICD or percentage of vessels and tumour stage 
(r = 0.12 and r=0.04). This is in agreement with the findings of Awwad et al (1986) 
who did not show a relationship between ICD and either tumour grade or stage of 
disease. However, Kolstad (1968) showed an association between a large ICD and an 
advanced stage of disease and by pooling Stages II, III and IV found a significant 
difference compared to the Stage I cases. When the same exercise was carried out with 
this series the difference between the mean ICD of Stage I tumours and the mean ICD of 
pooled Stage II, III and IV cases almost reached the 0.05 level of significance (p = 0.06). 
When more tumours in Stage III and IV are analysed, there may be a correlation of ICD 
with stage, suggesting that the more bulky tumurs have larger ICDs. 
93 
A number of studies have shown a correlation between the degree of vascularisation of a 
tumour and outcome following radiotherapy for the patients from whom the tumour 
biopsies were obtained (see Table 13). Awwad and colleagues (1986) showed a greater 
ICD in 15 patients who recurred within two years compared to 21 patients who remained 
well at two years. Siracka and colleagues (1982; 1984; 1988), in several retrospective 
studies of cervical carcinoma patients, showed a relationship between the vascular density 
and survival and Delides et al (1988) demonstrated this in a retrospective study of 25 
cases of nasopharyngeal tumour. In contrast, Lauk et al (1989), found a higher local 
control rate of oral squamous cell carcinoma among tumours which were less well 
vascularised. Whereas in the work reported here no correlation between local recurrence 
or survival time was found with the vascularity of a tumour (measured as ICD or 
morphometry). Although the follow up of the patients in this series is only two years, 
80% of the recurrences that will occur, should do so within the first two years (Perez et 
al, 1988). It is of note that an unpublished series by Delides (1988) on bladder cancer 
showed no correlation between vascular density and effectiveness of radiotherapy 
(Revesz et al, 1989). 
There are several possible explanations for the contradictory, nature of these results. 
Firstly different techniques have been used by the various groups investigating tumour 
vascularity. Lauk and colleagues used an anti-factor VIII stain and Awwad used an 
alkaline phosphatase technique to stain endothelial cells. Lauk and colleagues (1989) also 
raise the issue that the technique of Masson's trichrome staining with morphometric 
analysis may underestimate the vasculature of poorly differentiated tumours as open and 
plasma perfused vessels may be hard to recognise without specific endothelial staining. 
The morphometry technique of Siracka et al (1982; 1984; 1988) express vascular density 
as a percentage of the stromal and not of the tumour component except in their earliest 
report where the percentage of vessels was reported (means of 2.3% and 6.3% given for 
the two groups of tumours). This explains the higher values for the vascular density 
obtained compared with the percentage of vessels found in this series using 
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morphometry. Delides et al (1988) also used a different method in that the number of 
capillaries per high power field was used as a measure of vascular density. Secondly the 
biopsies assessed in this study are small punch biopsies whereas the studies of Siracka et 
Al (1988) and Revesz et al (1989) used surgically removed specimens to look at intra 
tumour variation in vascularity. In view of known tumour inhomogeneities sampling 
errors may confuse the situation. Thirdly, the majority of the studies are retrospective 
and have the disadvantage of patient selection (except the studies of Awwad and 
Kolstad). Also the patients in most of the studies are in selected stages of their disease 
(see Table 13); different radiotherapy schedules have been employed and investigations 
have been carried out on squamous cell carcinoma from different sites. These may all 
contribute to the varying results obtained. 
It is possible that a correlation exists between ICD and clinical outcome from 
radiotherapy, but this study has included all stages and grades of tumours which would 
be better analysed by a multivariate analysis. The majority of the specimens are from 
patients with Stage I or II disease (Stage I= 36; Stage II = 30) and the importance of 
stage and size of tumour along with the presence or absence of lymph node metastases 
will have a considerable bearing on treatment outcome. A multivariate analysis in this 
prospective study may yet show the importance of tumour vasculature in predicting 
outcome of treatment. 
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TABLE 14 RECURRENCE VERSUS DISEASE FREE 
VASCULARITY RESULTS 
RECURRENCES 
ICD 
193 
257 
213 
216 
234 
255 
197 
225 
219 
302 
256 
260 
274 
277 
208 
247 
333 
228 
DISEASE FREE 
% VESSELS ICD % VESSELS 
1.6 243 2.4 
1.6 223 1.4 
1.1 232 0.9 
1.7 185 3.5 
1.2 299 2 
1 298 3.3 
1 202 2.3 
2.4 187 3.7 
3.8 223 2.5 
1.3 248 2 
1.9 238 0.7 
3.9 208 1.8 
1.9 223 3.3 
1.0 255 7.0 
3.4 226 1.6 
3.6 256 0.9 
3.2 257 1.9 
3.4 
n=18 
mean=244±37 
range = 193.333 
median = 240µm 
% vessels 
mean = 2.16±1.07±. 25 
*median = 1.8% 
*(±1 SD ±1 SEM) 
minimum follow up =2 yrs 
n= 17 
mean - 235 ± 32 
range ='185 - 299 
median = 232µm 
% vessels 
mean = 2.42±1.49±. 36 
*median = 2% 
*(±l SD ±l SEM) 
i 
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6.2 INFLAMMATORY CELL INFILTRATES, 
The mean percentage of tumour cells in cell suspensions prepared from the tumour 
specimens, determined by May Grunwald-Giemsa staining and confirmed by monoclonal 
antibody staining with CK1 and/or CAM5.2 (Fig. 24), was 45 ± 15% (±1 sd) with a 
median of 43% and a range of 10-85% (n=116). The mean percentage of macrophages 
was 15% ± 7% (±1 sd) with a median of 14% and a range of 4-58%. The staining was 
confirmed by the monoclonal antibody EBM 11 (Fig. 25). In 106 specimens the 
percentage of tumour cells scored using both methods was in good agreement (less than 
10% difference between the two methods) except in 11 specimens where the percentage 
of antibody staining tumour cells was less than that of the May Grunwald-Giemsa 
staining method. However in these specimens there was good agreement between the 
EBM11 staining and the May Grunwald-Giemsa staining. Three specimens showed 
differences in the two methods when there was a higher percentage of EBM 11 staining 
cells than the percentage of macrophages on conventional staining. This may have been 
due to non-specific staining, as the percentage of tumour cells staining in these specimens 
was similar with the two methods. The percentage of lymphocytes ranged from 0.8 - 
48% with a mean of 16 ± 9% (±1 sd) and the percentage of granulocytes ranged from 1- 
81% with a mean value of 23 ± 16% (t1 sd). In 5% of the specimens (n=6) abundant 
eosinophils were seen on the cytospin preparations. 
The possible association between the proportions of host cells in the tumour specimens 
and clinical data were studied. The percentage of macrophages was not correlated with 
stage (r = 0.05), tumour differentiation (r ='-0.17) or patient age (r = 0.09). There was 
no relationship between the percentage of macrophages and CFE (r = -0.001) or with 
radiosensitivity, as measured by SF2, r=0.15. Similarly, no correlation was seen 
between the percentage of lymphocytes or granulocytes and tumour stage (r = 0.03, r= 
0.14), tumour differentiation (r = 0.07, 'r = 0.16) and patient age (r = -0.07, r= -0.13). 
The proportion of lymphocytes was not related to CFE (r =, O. 12) or SF2 (r = -0.05). No 
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relationship between the granulocyte percentage and CFE (r = 0.08) or SF2 (r = 0.11) 
was demonstrated. 
There was no significant variation in the percentage of tumour cells from two biopsies 
from the same specimens, processed independently, from 25 tumours (t = -0.5, p=0.6, 
DF = 45). The mean percentage of tumour cells in the suspensions from 12 tumours 
which had been stored in liquid nitrogen prior to processing was 51 ± 8% (±1 sd). This 
was not significantly different from the mean tumour cell percentage of the specimens 
processed immediately (t = -1.25, p=0.2, DF = 30). 
6.2.1 Discussion 
Infiltration of various stromal or host cells within and/or surrounding tumours has been 
reported to be associated with a good prognosis (Underwood, 1974; Svennevig, 1984; 
Steele, 1984; Luebbers, 1985). Therefore an attempt was made to quantify the host cell 
proportions in cell suspensions prepared from tumours and to look for correlations 
between the levels of inflammatory cells and other clinical and biological data. The 
proportions of host cells in the suspensions obtained from this series of cervical 
carcinomata were similar to those obtained in other series using solid tumour (lung, 
breast, colon and stomach tumours; Wood and Gollahan, 1977; Staren et al, 1979; Haas 
et al, 1990). While Svennenig et al (1979) reported lower proportions of lymphocytes 
and macrophages, possibly due to the mechanical method of dissaggregation used leading 
to selective losses. Although it has been shown that the percentage of tumour cells and 
macrophages obtained may be altered by enzyme disaggregation compared to values 
obtained using cryostat sections (Takeo et al, 1986; Costa et al, 1987). It has been 
demonstrated that considerable variation exists in the distribution of the inflammatory 
cells within tumours. Macrophages were reported in association with malignant tumours 
in a definable pattern which will not be seen with tumour cell suspensions (Whitworth et 
al, 1990) and also variation in the distribution of tumour infiltrating lymphocytes has 
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been described (Hiraysuka et al, 1984). Macrophages were shown to be aggregated 
around areas of necrosis (Svennenig et al, 1979). There are therefore likely to be 
sampling errors with the biopsies received which were taken from tumour areas remote 
from grossly necrotic areas. However, there were no significant differences shown in 
the percentage of host cells in the cell suspensions obtained with the 25 tumours where 
more than one biopsy was obtained and processed independently (p = 0.6), although the 
sampling was biased in that necrotic regions of the tumours were excluded. Eosinophils 
were seen to feature prominently in 6 specimens (5%) which is similar to the proportion 
(3%) reported by Lowe (1988) in a large series of cervical carcinomata (1027 cases). In 
Lowe's series these patients had a better prognosis, though Bostrom (1981) found no 
correlation between tumour eosinophilia and prognosis. 
The in vitro growth of cervical carcinoma in this series was not influenced by the 
percentage of macrophages (r = -0.00 1) or by the proportions of lymphocytes (r = 0.12) 
in the tumour suspensions which is is agreement with a published series looking at 
ascites and pleural effusions (Hofmann et al, 1984). It has been reported that 
macrophages can promote the growth of tumour cells in vitro (Buick et al, 1980; Gabizon 
et al, 1980) with evidence that this growth promotion is mediated by soluble factors 
(Gabizon et al, 1980). These are possibly the same as those factors secreted by 
peripheral blood monocytes which enhance the growth of human tumours in soft agar 
and appear to be non-dialiazable, heat stable, acid labile proteins of 10,000 - 30,000 
daltons (Hamburger et al, 1986; 1987). However, in this study no correlation was 
demonstrated between the percentage of macrophages or lymphocytes and CFE. 
The macrophage content of the tumours was not demonstrated to be associated with 
radiosensitivity (r = 0.15) in this series. In contrast, the work of Milas and associates 
(1987) demonstrated that murine tumours with higher macrophage content were more 
radioresistant than those containing fewer macrophages with the suggestion that 
macrophages promoted the growth of surviving tumour cells. However this was a small 
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series of murine tumours which may well differ from the behaviour of human tumours. 
This work reports the findings, thus far, on a large prospective series of one tumour type 
and the results are similar to the findings of Steele et al (1984) on a series of 40 breast 
tumours in that the macrophage content was not significantly associated with any one 
prognostic factor. However, in the high risk group of patients the number of 
macrophages was shown to be higher (Steele et al, 1984). Kelly et al (1988) failed to 
show any correlation between macrophage content and tumour grade or stage in a small 
series of breast carcinomas (n = 17). This contrasts with the findings of Whitworth et al 
(1990) who describe fewer macrophages in larger more advanced tumours (Normann, 
1985). The geometry of large solid tumours may be a factor reducing macrophage 
invasion into these tumours (Bugelski et al, 1987). As no correlation with stage was 
demonstrated in this study, sampling errors may be operating. Macrophages from 
tumours as with other sites of the body, display heterogeneity (McBride, 1986), though 
TAM subpopulations were not studied here which may have differences in function and 
influence on the tumour. 
6.3 Ki67 INDEX 
The Ki67 index 
the number of positive cells 
the total number of cells 
expressed as a percentage x proportion of tumour cells 
The Ki67 staining was carried out on cytospins from 90 of the 117 tumour specimens. 
However 49 specimens (54%) were negative for this antibody and cytoplasmic staining, 
without nuclear staining, occurred in 12 specimens (29%). Nuclear staining resulted in 
29 specimens giving a mean percentage of positive cells of 20.5% ± 23% and a range of 
0.9 - 94% (Fig. 27). These values have been corrected for the proportion of tumour cells 
in the cell suspensions. Cytospins of the cervix line CaSki from 7 day and 14 day 
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cultures were used as positive controls for the Ki67 staining (Fig. 26) and 3T3 cells were 
used as negative controls. The 7 day cultures of CaSki gave 70 - 85% positive nuclear 
staining and the 14 day cultures gave 16 - 25% positivity with Ki67. Double staining 
was carried out with Ki67 and CK 1, CAM5.2 or EBM 11 on 17 specimens which 
confirmed that the Ki67 positive cells were among the cells that stained for low molecular 
weight cytokeratin antibody (Fig. 28). Possible associations between the Ki67 index and 
the other parameters under investigation were studied. The Ki67 index was not related to 
tumour stage (r = 0.58), tumour differentiation (r = 0.02) or tumour age (r = -0.03). 
There was also no correlation between Ki67 staining and CFE (r = 0.04) or 
radiosensitivity as measured by SF2 (r = -0.07). 
6.3.1 Discussion 
The staining of the frozen cytospin preparation from cervical carcinoma resulted in only 
25% of the specimens which were labelled. Half the specimens (n = 49) were negative 
for Ki67 staining. However 21/50 (58%) of specimens which had been stored less than 
1 year were positive for Ki67 in this series. Walker and Camplejohn (1988) reported 
56% staining in their series of breast carcinomata using cryostat sections and Bouzubar et 
al (1989) reported 54% staining in their series of breast carcinomas. Only 10% of 
cytospins which had been stored in a freezer longer than a year were positive (n = 60). 
Some of these specimens (n = 8) were acetone fixed before storage, but this did not result 
in positive staining in these specimens. Walker and Camplejohn (1988) looked at storage 
times of 7 days (in liquid nitrogen) compared to immediate staining and found no 
difference in the proportion staining. However when studying the specimens in this 
series which were stained within I month of processing, a few specimens 3/9 were 
negative for Ki 67 with 2 of these showing cytoplasmic staining only. It is clearly not 
feasible to carry out Ki67 staining on specimens stored for longer than 1 year at -20°C. 
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The range of proportions of cells staining with Ki67 in this series was 0.9 - 94%. This 
compares with the range of <I - 60% in the study of Walker and Camplejohn (1988) and 
10-50% in the study of Brown et al (1988) on cervical carcinoma and 10-80% of ton 
Hodgkin's lymphoma cells (Schrape et al, 1987). Cytoplasmic staining was seen in 25% 
of specimens and 18% were negative in the series of Bouzubar et al (1989). Cryostat 
sections were used in the study of Brown et al and it was found that 4/31 specimens 
(13%) showed cytoplasmic staining and had to be excluded from the study. Gerdes et al 
(1983) reported nuclear and cytoplasmic staining in normal human epidermal cells but do 
not state the percentage in which this was demonstrated. In this study on cervix tumours 
29% of specimens showed cytoplasmic staining alone but only 12% of the specimens 
stored less than 1 year showed cytoplasmic staining. The low proportion of cells staining 
in this work may be due to the disaggregation procedures used on the cells which may 
alter the binding of the antibody. However, the porportions of Ki67 staining cells were 
not dissimilar from other reported series (Walker and Camplejohn, 1988; Brown et al, 
1988). It is more probable that the periods and temperature of storage are important 
factors. 
The positive controls (CaSki cells at 7 and 14 days) were positive with each batch of 
staining and the negative control remained unstained demonstrating that the antibody was 
active. The proportions of the exponential cells and plateau phase cells staining were 
similar to MCF-7 staining carried out by Bouzubar et al (1989). Given the low 
proportion of the specimens which stained for Ki67 (25%) it is perhaps not surprising 
that no association was seen with tumour stage though the majority of the specimens 
were Stage I (Stage I= 13, Stage II = 8, Stage III =6 and Stage IV = 1) and the numbers 
of advanced tumours were small. There was no association with grade or patient age. 
No correlation was seen when these parameters were investigated in the large series 
reported by Bouzubar et al (1989), though an association with grade was demonstated by 
the work of Gerdes et al (1986). 
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The double staining demonstrated that Ki67 positivity in tumour cells though several 
series have reported staining in normal cells but in low proportions (Gerdes et al, 1983; 
Bouzubar et al, 1989) although Charpin et al (1989) demonstrated Ki67 staining in 
epithelial cells only in their series of breast carcinoma aspirates. 
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5) 
LIST OF CONCLUSIONS 
Radiosensitivity. This work has demonstrated a wide range of inter-patient 
SF2 values. The assay results were shown to be reproducible and intra-tumour 
heterogeneity was not a limitation of this assay. Significant differences between 
the mean SF2 for different tumour histologies were obtained. 
Clonogenicity. The CFE was shown not to be associated with tumour 
stage, tumour differentiation or patient age. It was not associated with 
radiosensitivity as measured by SF2. 
Vascularity. Two methods of assessing vascularity namely measuring ICD 
and proportion of vessels were compared. Neither of these parameters were 
related to tumour stage, tumour grade, patient age or tumour histology. Data 
from patients with 2 year minimum follow up revealed no differences between 
the mean proportion of vessels or ICD in the tumours in the group of patients 
that recurred and the group which remained disease free. 
Inflammatory infiltrates. The proportions of macrophages and 
lymphocytes were not shown to be associated with CFE, SF2, Ki67 staining, 
tumour stage or differentation. 
Ki67 index. = No relationship with tumour stage or differentiation was 
shown with the proportion of positively staining nuclei with Ki67. It was 
shown that the cytospins which were stored for more than 1 year were either 
negative for Ki67 or showed cytoplasmic staining. 
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NO. ICD RANGE ISD HISTOLOGY MORPHOMETRY % relative volumes 
x pm x pm Parenchyma Stroma Vessels Necrosis 
V3 290 ' 79.8-568 145 P. SCC 58.9 37.2 2.3 1.7 
V4 193 86-435 - P. SCC 56.4 41 1.6 1.1 
VS 257 96-397 105 P. adeno. 69.3 5.3 1.6 23.4 
V7 Too small to score 
V8 243.5 3-444 - M. adeno. 75 19.9 2.4 2.7 
V9 257 122.8-428 - W. SCC 86.1 7.9 1.9 4.1 
V10 213 109-359 - P. SCC 77.1 19.9 1.1 1.8 
V11 223 110-402 - P. SCC 65.1 25.6 1.4 8.0 
V12 No tumour on block 
V13 215.5 8.6-483 - P. SCC 50.3 33.6 1.7 14.4 
V14 234 35-416 - P. small cell 81.2 13.8 1.2/0.8 3.9 * 
V15 255 93-494 149 P. SCC 92.9 4.6 1.0 1.5 
V16 197 90-332 - M. SCC 72.3 18.1 1.0 8.6 
V17 225 5.6-513 - P. SCC 28.8 26.7 2.4 42 
V18 CIN on biopsy 
V19 218.5 54.7-399 - M. SCC 63.6 32.8 3.8 0 
V20 302 96.6-495 - M. SCC 63.4 27 1.3 8.4 
V21 Too small to score 
V22 232 123-509 - M. SCC 58.1 31.4 0.9 9.6 
V23 256 78-495 190 P. SCC 68.4 9.3 1.9 20.4 
V24 260 107-410 - M. SCC 55.9 35.9 3.9 5.2 
V25 185 79-363 - W. adeno 34.7 57.2 3.5 4.9 
V26 274 79.6-538 170.8 M. SCC 74 8.3 1.9 15.8 
V27 299 137-663 - M. SCC 52 32 2.0 14 
V28 298 4-504 - P. SCC 20.4 54.7 3.3 21.6 
V29 202 4.3-362 - W. SCC 26.4 61.1 2.3 10.2 
V30 277 119-468 - P. SCC 51.1 37.7 1.0 10.2 
V31 187 94-357 - M. SCC 88.2 6.1 3.7 1.5 
V32 208 53-445 - W. SCC 60.9 20.5 3.4 15.2 
V33 202 93-346 - P. SCC 43 28.6 3.3/3.0 25.1* 
V34 244 80-452 - P. SCC 65.8 16.8 5.3 12.1 
V35 246.8 8.6-514 - M. SCC 67 25.1 3.6 4.3 
V36 223 87-364 - W. adeno 62.3 31.7 2.5 3.5 
V37 248 107.8-433.5 - W. SCC 87.2 9.0 2.0 1.8 
V38 237.5 56.8-448 - M. SCC 93.3 3.8 0.8/0.6 2.2* 
V39 256 4.8-544 - M. SCC 82.7 14.2 0.9 2.2 
127 
NO. ICD 
x µm 
RANGE ISD 
x pm 
HISTOLOGY MORPHOMETRY % 
Parenchyma Strome Vessels Necrosis 
V40 259 68-494 - P. SCC 49.8 37.4 5.8/3.4 8.2* 
V41 226.4 12-570 - M. SCC 78.1 18.0 1.6 2.3 
V42 CIN only on block 
V43 333 92-609 - M. SCC 37.5 53.4 3.2 6.0 
V45 208 85-456 133 W. SCC 59.2 37.7 1.2/2.7 1.4* 
V46 223 73-394 - M. SCC 43.2 43.7 3.3 9.8 
V48 228 81-489 - M. SCC 42.9 47.2 3.4 6.5 
V49 254.8 128-613 - M. SCC 70.6 8.2 7.0 14 
V50 Too small W. SCC 
V51 287 74.5-656 - M. SCC 66.8 30.3 1.4 1.5 
V52 229 84-396 - W. SCC 53.7 32.1 2.1 12.1 
V53 214 108-412 - W. SCC 63.1 32.1 2.2 2.6 
V54 285 11.8-610 114 W. SCC 75.9 15.9 1.0/1.2 7.2* 
V55 Too small M. SCC 
V56 Too small 
V57 257 86-496 - P. SCC 51.9 31.6 1.1 15.4 
V58 214 100-387 - P. SCC 85.3 10.1 1.8 2.8 
V59 280 48.7-522 - P. SCC 67.3 18.4 2.3 12 
V60 250 119-442 - M. SCC 72.4 21.9 1.3 4.4 
V61 272 96-488 - P. SCC 74.5 18.7 1.1 5.7 
V63 274 5-478 144 M. SCC 63.9 19.9 3.7 12.6 
V64 170 7-295 - M. SCC 31.2 56.9 2.4/2.6 9.4* 
V65 257.5 12-587 - M. SCC 57.4 32.1 2.1 8.5 
V66 215 58-440 115.4 M. SCC 61.8 25.3 2.7 10.3 
V67 275.6 3-474.6 - W. SCC 38.3 53.1 2.5 6.2 
V69 239 4.8-335 - M. SCC 67 27.3 2.7 3.0 
V70 130.5 55.6-368.5 - M. adeno 37.7 52.3 4.3 5.8 
V71 226.6 5.6-403 138.8 P. adeno. sq. 84.2 11.1 2.5 2.0 
V72 Too little tu mour on block 
V73 322 162-668 - M. SCC 40.9 45.3 11 3.3 
V74 241 69-484 - P. SCC 79.3 14.5 3.1 3.2 
V75 199 6-539 - P. SCC 58.2 26.8 6.5 8.5 
V76 231 56.8-514 - M. SCC 63.1 29.6 3.1 4.3 
V77 328 112-593 P. SCC 86.9 5.6 0.6 6.9 
V78 221 42.8-554 - M. SCC 64.3 27.3 1.5 6.9 
V79 263 135-476 M. SCC 49.3 41.7 2.2/2.4 6.7* 
V80 207 , 58-470 - M. SCC 71.6 24.4 2.5 1.6 
V81 239 94-361 - W. SCC 62.8 29.6 2.1 5.6 
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NO. ICD RANGE ISD HISTOLOGY MORPHOMETRY % 
X AM x }im Parenchyma Strome Vessels Necrosis 
V82 252 68.8-585 - W. SCC 64.6 20.9 4.2 10.6 
N83 260 79.6-518 - W. SCC 81.5 11.5 3.7 3.3 
V84 232 66-509 - M. SCC 68.4 21.5 23 7.8 
V85 248 144-537 M. SCC 75.5 15.0 2.1 7.2 
V86 183.5 77-384 - M. SCC 62.3 13.8 5.1 18.8 
V87 191 74-309 - P. adeno 60.1 14 2.5 23.4 
V88 246 110-441 - M. SCC 67.1 26.4 1.9 4.6 
V89 219 7.2-557 119 M. SCC 62.9 30.1 2.6/1.6 5.0* 
V90 220 77-459 - P. SCC 68 19.4 1.3 11.4 
V91 277.6 88-558 - W. SCC 60.9 34.0 0.8 4.3 
V92 181 65-379 W. SCC 52 42.1 3.3 2.8 
V93 228 98-528 - W. SCC 56.5 39.8 3.6 0.4 
V94 210 86-357 - P. SCC 68.5 25.7 4.8 1.0 
V95 250 93-477 - W. SCC 49.2 43.8 4.1 2.9 
V96 289.9 120-535 - M. SCC 65.5 27.9 3.8/2.6 3.8* 
V97 183 103-321 - P. SCC 60 28.8 2.5 8.8 
V98 Too small M. SCC 
V99 228 80-252 - M. SCC 76 19 4.5 0.7 
v loo 197 105-381 - M. adeno 64.9 26.6 7.2 1.3 
V10l 235 74-465.8' - P. SCC 57.6 25.6 2.2 14.8 
V102 Too small MCC 
V103 Too small 
V104 Too small 
V106 314 119-648 - M. SCC 63.7 31.5 2.7 2.3 
V107 263 97-446 - 71.4 25 1.2 1.7 
APPENDIX 2 VASCULARITY RESULTS 
ICD = intercapillary distance; ISD = intercapillary distance in stroma; 
W. SCC = well differentiated squamous cell carcinoma 
M. SCC = moderately differentiated squamous cell carcinoma 
P. SCC = poorly differentiated squamous cell carcinoma 
*2 biopsies assessed separately for morphometry 
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no of specimens studied - 90 
APPENDIX 3 Ki67 RESULTS 
CaSki at 7 days 70-85% +ve 
CaSki at 14 days 16-25% +ve 
( UNCORRECTED FOR % TUMOUR CELLS ] 
[ [in parentheses] corrected for % TUMOUR CELLS ] 
V4 cytoplasm only 
V5 neg 
V6 neg 
V7 cyto only 
V8 6.8 [27.21 
V 10 cyto only 
V 14 neg 
V15neg 
V16neg 
V17 neg 
V20 
V23 cyto only 
V24 neg 
V28 neg 
V29 neg 
V30 neg 
V32 neg 
V34 neg 
V37 B5 [6.8] 
V38 A and B neg 
A2 [4.81 
V61B 1.5 [3.61 
V62 cyto only 
V63 neg 
V64 neg 
V66 neg 
V67 neg 
V69 neg 
A 0.5 [0.9] 
V70 B 1.6 [2.6] 
V7 IA and B neg 
V72 neg 
V74 B neg 
V75 A and B neg 
V76 A and B neg 
V77 A and B neg 
V78 neg 
V79 neg 
V80 neg 
V81 A neg 
V96 neg 
V97 6.3 [13.41 
A5 [9.3] 
V99 B 8.3 [14.9] 
A 29 
V100 B 1.3 [58] 
A 
V 10l B neg 
V102 neg 
A 0.6 [1.5] 
V103 B 0.8 [1.9] 
V104 5.5 [16] 
V105 neg cyto staining 
V106 1.5 [3] 
V107 neg 
V108 A cyto only 
V108 B 2.2 [4.8] 
V109 A2 [3.8] 
V109 B 2.4 [4.2] 
V110 neg 
V111 A12.7[921 
V111 B 14 [54] 
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[ UNCORRECTED FOR % TUMOUR CELLS ] 
[ [in parentheses] corrected for % TUMOUR CELLS ] 
V40 A 0.6 [0.9] V82 A neg V112 9.4 [24.6] 
V41 neg V83 A neg VI 13 A 7.3 [26] 
V42 neg V84 A and B neg V113 B11.4[30.81 
V43 neg V85 neg V 114 cytoplasm only 
V44 neg V86 neg V115 A4.3 [21] 
A16.6 [54] 
V46neg V87B12.8[38] V115 B 6.3 [17.6] 
A cyto only 
V47 neg V88B 4.3 [7.4] V116 27 [81] 
A 6.6 [20] 
V51 neg V89 B 8.3 [22] V 117 cyto only 
V52 neg V90 8 [32.5] V118 15.2 [40.6] 
V53 neg V91 A and B cyto only 
V54 B 5.3 [16] V92 2 [3.5] 
V55 cyto only 
V56 neg 
V57 2.4 [5.51 
V59 5.6 [11.81 
V60 cyto only 
A neg 
V93 B 2.6 [3.7] 
A 7.3 [20] 
V94B5.3 [16] 
V95 neg 
positive cells 
Ki67 score = expressed as a 
total no. of tumour cells percentage 
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APPENDIX 5 PATIENTS WITH RECURRENCE/DIED 
(* metastatic disease outside pelvis only) 
V2 Dead 19 months 
V3 Died from metastases from carcinoma of breast 
V4 Recurrence at 14 months. Died at 23 months with pelvic recurrence and mets V5 Died at 6 months. Recurrence after Wertheims and metastases 
* V6 Died with metastatic disease at 20 months 
V 10 Died at 17 months 
* V13 Died at 29 months metastatic disease 
V14 Died at 1 months. Stage IVB disease 
V15 Recurrence at 10 months 
V16 Died at 11 months with pelvic disease 
V17 Died at 7 months. Palliative XRT. Also had carcinoma of the breast 
* V19 Died at 7 months metastases in brain and lung 
V20 Died at 23 months with pelvic disease and mets 
* V23 Died at 19 months with metastases 
V24 Died at 19 months. Had pelvic disease 
V26 Died at 14 months. Disease in pelvis 
* V30 Died at 15 months. Stage NB at presentation, so palliative RT 
* V32 Recurrence at 17 months and mets 
V33 Palliative RT 
V35 Recurrence NB disease 
V40 Palliative RT 
* V43 Died with metastases at 13 months 
V48 Stage NB disease, died at 8 months 
V50 Recurrence at 21 months 
* V51 Died at 10 months 
V52 Died at 5 months with pelvic disease 
* V53 Died at 15 months with metastases 
V55 Recurrence at 18 months 
V58 Recurrence at 21 months 
* V63 Died with pulmonary metastases 11 months 
V67 Died with pelvic disease and mets 11 months 
*[V75 Died at 11 months. No cancer found at PM] 
* V77 Died at 3 months. Palliative RT because of metastases 
V80 Recurrence 
V81 Died 13 months with recurrence. Recurrence following surgery, palliative RT 
V82 Died at 7 months, residual disease. Palliative RT 
V87 Vaginal recurrence at 9 months 
V90 Recurrence 
V91 Died at 11 months with pelvic recurrence 
V96 Recurrence and paraaortic metastases 
* V97 Died of metastases at 11 months 
[up to VSO - minimum 2 yr follow up; up to V97 1 yr minimum follow up] 
o3r 
